Furan-fused ring-substituted glutarimide compounds

Abstract

The present invention discloses a series of furan-fused ring substituted glutarimide compounds and their use in the manufacture of medicaments for treating related diseases, specifically, the compound represented by formula (II) and its pharma-ceutically acceptable salts: JPEG2024511342000119.jpg6576

Description

[Technical field]

[0001] This application claims priority to: CN202110286500.6, application date: March 17, 2021; CN202110712765.8, filing date: June 25, 2021; CN202111314330.4, filing date: November 8, 2021; CN202210187905.9, application date: February 28, 2022.

[0002] The present invention relates to a series of furan-fused ring substituted glutarimide compounds and their use in the manufacture of medicaments for treating related diseases, in particular to the compound represented by formula (II) and its pharma-ceutically acceptable salts: [Background technology]

[0003] Because androgen receptor signaling plays an important role in the pathogenesis of prostate cancer and is known to be involved in the development of other androgen receptor-positive cancers, inhibition of androgen receptor signaling with antiandrogens that antagonize the androgen receptor has been used or proposed for use in the treatment of prostate cancer.

[0004] The AR gene encodes the androgen receptor protein, whose ligands are mainly testosterone and dihydrotestosterone, and the receptor is widely distributed in most organs and tissues of the human body and mediates the biological effects of androgens. The androgen receptor can bind to heat shock proteins (Hsp) in the cytoplasm. When androgens bind to the androgen receptor, the receptor is activated, the heat shock proteins are dissociated, and the androgen receptor forms a dimer and enters the nucleus, where it binds to the androgen response element (ARE) on DNA, initiating the transcription and expression of a series of genes downstream of the element, including genes such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP) and cyclin-dependent kinase (CDK) inhibitor p21WAF1 / CIPI, ultimately resulting in cell differentiation and promoting the development of tissues and organs. Androgens function to maintain the growth and development of the prostate. In an androgen-free environment, prostate cells spontaneously undergo apoptosis, but in an environment with normal androgen levels, prostate cells can continue to grow and differentiate. Thus, some studies suggest that both excessive secretion of androgens and excessive responsiveness of the androgen receptor lead to uncontrolled proliferation of prostate cells and are risk factors for the development of prostate cancer.

[0005] Prostate cancer (PCa) is one of the most commonly diagnosed non-skin cancers in men in the United States and the second leading cause of cancer death, with over 200,000 new cases and over 30,000 deaths in the United States each year. Androgen deprivation therapy (ADT) is the standard of care for advanced PCa. Patients with advanced PCa receive ADT with luteinizing hormone releasing hormone (LHRH) agonists, LHRH antagonists, or bilateral orchiectomy. Despite an initial response to ADT, disease progression is inevitable and the cancer presents as castration-resistant prostate cancer (CRPC). Up to 30% of prostate cancer patients treated with primary radiation or surgery will develop metastatic disease within 10 years of primary treatment. Approximately 50,000 patients will develop metastatic disease each year, referred to as metastatic CRPC (mCRPC).

[0006] Proteolysis Targeting Chimera (PROTAC) is a technology that applies the ubiquitin-proteasome system to target specific proteins and induce their intracellular degradation. The ubiquitin-proteasome system is the main pathway for intracellular protein degradation and is primarily responsible for removing denatured, mutated or harmful proteins from cells as a normal physiological function, with more than 80% of intracellular protein degradation dependent on the ubiquitin-proteasome system. PROTAC utilizes the cell's own protein destruction mechanism to remove specific target proteins in cells.

[0007] The present disclosure describes compounds, including compositions of matter, that function to recruit endogenous proteins to E3 ubiquitin ligases, such as cereblon (CRBN) E3 ubiquitin ligase, for ubiquitination and subsequent degradation, as well as methods of using the same. In particular, the present disclosure provides bifunctional or proteolysis-inducing chimeric molecules (PROTAC) compounds that have been found to act as modulators of targeted ubiquitination and androgen receptor (AR) degradation. Summary of the Invention

[0008] The present invention provides a compound represented by formula (II) or a pharma- ceutically acceptable salt thereof. [ka] however, The PTM is selected from a drug or a derivative thereof that targets and binds to an AR protein; L1 is -(CH2) n -, wherein each CH2 is optionally substituted by R1; R1 is C 3-7 Cycloalkyl, 6-membered heterocycloalkyl, -NR a -, -CR b R c -, -CH2CH2O-, and -NHC(=O)-; R a H and C 1-3 alkyl, R b , R c is selected from H, D and F; E1 is selected from a single bond and O; Ring A is absent, or Ring A is selected from phenyl and 5-membered heteroaryl; n is selected from 1, 2, 3, 4, 5, and 6; the 6-membered heterocycloalkyl and 5-membered heteroaryl each contain 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from -NH-, -O-, -S-, and N; The proviso is that the compound is not selected from the following formulae: [ka]

[0009] In some embodiments of the invention, the PTM is [ka] and the other variables are as defined herein.

[0010] In some embodiments of the present invention, the R a is selected from H and CH3, and the other variables are as defined herein.

[0011] In some embodiments of the present invention, R1 is cyclopropyl, cyclohexyl, piperazinyl, piperidinyl, -NR a -, -CH2CH2O-, -NHC(=O)-, and -C(=O)NH-, the other variables being as defined herein.

[0012] In some embodiments of the present invention, R1 is [ka] is selected from -NH-, -N(CH3)-, -CH2CH2O-, -NHC(=O)-, and -C(=O)NH-, the other variables being as defined herein.

[0013] In some embodiments of the present invention, R1 is [ka] is selected from -N(CH3)-, -CH2CH2O-, and -NHC(=O)-, the other variables being as defined herein.

[0014] In some embodiments of the present invention, L1 is [ka] and the other variables are as defined herein.

[0015] In some embodiments of the present invention, the structural unit -E1-L1- is [ka] and the other variables are as defined herein.

[0016] In some embodiments of the present invention, the structural unit [ka] and the other variables are as defined herein.

[0017] In some embodiments of the present invention, the compound is selected from structures represented by formulas (I-1), (I-2), (II-1), (II-2), (III-1) and (IV-1). [ka] however, L1 is as defined herein.

[0018] The present invention provides a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof. [ka] however, E1 is selected from a single bond, O and NH; E2 is a single bond and C 1-3 alkyl, E3 is C 1-3 selected from alkyl and cyclopropyl; E4 is selected from a single bond and -C(=O)NH-; Ring A is absent, or Ring A is selected from phenyl; The ABM is selected from a drug or a derivative thereof that binds to an AR target protein. In some embodiments of the present invention, the structural unit -E1-E2- is selected from a single bond and -OCH2CH2-, with other variables as defined herein.

[0019] In some embodiments of the present invention, the structural unit -E3-E4- is 1-3 Alkyl, [ka] and the other variables are as defined herein.

[0020] In some embodiments of the present invention, the structural unit [ka] and the other variables are as defined herein.

[0021] In some embodiments of the invention, the ABM is selected from the structure of formula (ABM-1): [ka] however, R1 and R2 are selected from methyl; Or, R1 and R2 may be a carbon atom and a C 4-6 Forming a cycloalkyl, Y1 and Y2 are each independently selected from O and S; Ring B is selected from phenyl and pyridyl, said phenyl and pyridyl optionally containing one, two or three R a is replaced by Ring C is selected from a single bond or phenyl, said phenyl optionally containing one, two or three R b is replaced by R a is selected from F, Cl, Br, I, CN, CH3, CF3 and NO2, R b is selected from F and Cl.

[0022] In some embodiments of the invention, the ABM is selected from structures of formulas (ABM-1a) and (ABM-1b): [ka] however, T1 is selected from CH and N; R b1 is selected from H and F; n is selected from 1, 2 and 3; Y1, Y2, R a , R1 and R2 are as defined in the present invention.

[0023] In some embodiments of the invention, the ABM comprises: [ka] is selected from.

[0024] In some embodiments of the invention, the compound is selected from structures represented by formulas (I-1a) and (I-2a). [ka] however, T1, R1, R2, R a , R b1 , n, E1, E2, E3 and E4 are as defined in the present invention.

[0025] Some aspects of the invention are further formed by any combination of the variables listed above. The present invention also provides the following compound or a pharma- ceutically acceptable salt thereof: [ka] [ka]

[0026] The present invention also provides the following compound or a pharma- ceutically acceptable salt thereof: [ka] [ka] [ka]

[0027] The invention also provides the use of the above compound, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating prostate cancer.

[0028] [Definitions and Explanations] Unless otherwise stated, the following terms and phrases used herein have the following meanings. A particular term or phrase, unless otherwise defined, should be understood as being of ordinary definition, not indefinite or unclear. When a trade name is mentioned in this specification, it refers to the corresponding product or its active ingredient.

[0029] As used herein, "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are within the scope of sound medical judgment, suitable for contact with human and animal tissues, without significant toxicity, irritation, allergic response or other problem or complication, and consistent with a reasonable benefit / risk ratio.

[0030] The term "pharmaceutical acceptable salt" refers to a salt of a compound of the present invention, which is prepared with a relatively non-toxic acid or base with a compound having certain substituents discovered in this invention. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral forms of these compounds with a sufficient amount of base in a single solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral forms of these compounds with a sufficient amount of acid in a single solution or in a suitable inert solvent. Examples of pharma- ceutically acceptable acid addition salts include inorganic and organic acid salts, as well as salts of amino acids (such as arginine) and organic acids such as glucuronic acid, such as inorganic acids including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like, and organic acids including, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and the like. Certain compounds of the present invention contain both basic and acidic functional groups and can therefore be converted into any suitable base or acid addition salt.

[0031] The term "drug or derivative thereof" includes drugs or derivatives thereof that are developed to bind to target proteins. The pharma- ceutically acceptable salts of the present invention can be synthesized in a conventional manner from the parent compound which contains an acidic or basic group. Typically, such salts are prepared by reacting the compound in its free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture of both.

[0032] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as mixtures enriched in enantiomers or non-enantiomers, and all such mixtures are within the scope of the present invention. Other asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and mixtures thereof are both within the scope of the present invention.

[0033] Unless otherwise stated, the terms "enantiomers" or "optical isomers" are stereoisomers that are mirror images of each other. Unless otherwise explained, the term "diastereomer" is a stereoisomer whose molecules have two or more centers of chirality and whose molecules are not mirror-images of each other. Unless otherwise specified, "(+)" means dextrorotatory, "(-)" means levorotatory, and "(±)" means racemic.

[0034] [ka]

[0035] Unless otherwise specified, when a group has one or more available bonding sites, any one or more of the sites on the group can be bonded to another group by a chemical bond. The chemical bond by which the site is bonded to the other group is: [ka] For example, the straight solid bond in -OCH3 indicates that the group is connected to another group through an oxygen atom in the group; [ka] The straight dashed bond indicates the connection to other groups through both ends of the nitrogen atom in the group; [ka] The wavy lines indicate bonds to other groups through the one and two carbon atoms of the phenyl.

[0036] The compounds of the present invention can exist in a specific form. Unless otherwise stated, the term "tautomer" or "tautomeric form" refers to isomers of different functional groups that are in dynamic equilibrium at room temperature and can be rapidly converted between each other. Tautomers can reach chemical equilibrium of tautomers if possible (e.g., in solution). For example, proton tautomers (also called prototropic tautomers) include interconversions via the transfer of protons, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by rearrangement of some bond electrons. Among them, a specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.

[0037] Unless otherwise explained, the terms "enriched in one isomer," "isomer-enriched," "enriched in one enantiomer," or "enantiomer-enriched" mean that the amount of one isomer or enantiomer is less than 100% and that the amount of such isomer or enantiomer is 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.6% or more, or 99.7% or more, or 99.8% or more, or 99.9% or more.

[0038] Unless otherwise stated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, then the isomeric or enantiomeric excess (ee value) is 80%.

[0039] Optically active (R)- and (S)-isomers, as well as D- and L-isomers, can be prepared using asymmetric synthesis or chiral reagents or other conventional techniques. A single enantiomer of a compound of the invention can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary is decomposed to provide the desired isolated enantiomer. Alternatively, if the molecule contains a basic (e.g., amino) or acidic (e.g., carboxyl) functional group, the diastereomeric salt can be formed with a suitable optically active acid or base, followed by separation of the diastereomers by conventional methods known in the art, followed by recovery to provide the isolated enantiomers. Separation of enantiomers and diastereomers is also typically accomplished by chromatographic techniques using chiral stationary phases and in combination with any chemical derivatization method (e.g., formation of carbamates from amines).

[0040] The compounds of the present invention may contain unnatural atomic isotopes at one or more atoms constituting the compounds. For example, tritium (3 H), iodine-125( 125 I) or C-14( 14 Compounds can be labeled with radioisotopes such as radioisotopes C). Also, for example, deuterium can be replaced with hydrogen to form deuterated drugs, where the bond formed between deuterium and carbon is stronger than the bond formed between normal hydrogen and carbon, and compared to non-deuterated drugs, deuterated drugs have the advantages of reduced toxic side effects, increased drug stability, improved therapeutic efficacy, and extended biological half-life of the drug. Conversion of the isotopic composition of the compounds of the invention, whether radioactive or not, is within the scope of the invention.

[0041] The terms "optionally" and "optionally" refer to the event or circumstance described below that may, but does not necessarily, occur, and the description includes instances where the event or circumstance described does not occur.

[0042] The term "substituted" refers to the replacement of any one or more hydrogen atoms at a particular atom with a substituent, which may include deuterium and hydrogen variants, provided that the particular valence state is correct and the compound is stable after the replacement. When the substituent is a keto group (i.e., =O), it means that two hydrogen atoms are replaced. Keto group substitution does not occur in aromatic groups. The term "optionally substituted" refers to either substituted or unsubstituted, and unless otherwise defined, the type and number of substituents are any that are chemically stable and can be realized.

[0043] The term "substituted" refers to the fact that the particular atom or group may be replaced with the particular other atom or group. For example, the CH2 in CH3CH2CH3 can be replaced by O, S, NH to give CH3OCH3, CH3SCH3, and CH3NHCH3.

[0044] When any variable (e.g., R) occurs more than once in a composition or structure of a compound, its definition is independent in each occurrence. Thus, for example, if a group is substituted with 0-2 R, then said group is optionally substituted with up to 2 R, and each occurrence of R is independently optional. Also, combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0045] When the number of linking groups is 0, for example, -(CRR)0- means that the linking group is a single bond. The absence of a substituent represents that the substituent is not present, for example, the absence of X in AX represents that the structure is actually A. When no atom through which a substituent is substituted for a given substituent is specified, such a substituent may be bonded through any atom thereof, for example, pyridinyl as a substituent may be bonded to the substituent through any carbon atom of the pyridine ring.

[0046] Unless otherwise defined, the term "C 1-3 "Alkyl" refers to a saturated hydrocarbon group consisting of 1 to 3 carbon atoms in a straight or branched chain. 1-3 Alkyl has C 1-2 and C. 2-3 Alkyl, which may be monovalent (e.g., methyl), divalent (e.g., methylene) and polyvalent (e.g., methine). 1-3 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl).

[0047] Unless otherwise stated, the number of atoms in a ring is generally defined as the number of ring members, e.g., a "5- to 7-membered ring" refers to a "ring" of 5 to 7 atoms arranged around it. Unless otherwise defined, "C 3-7 "Cycloalkyl" refers to a saturated cyclic hydrocarbon group composed of 3 to 7 carbon atoms, which includes monocyclic and bicyclic ring systems, where bicyclic ring systems include spiro rings, fused rings and bridged rings.3-7 Cycloalkyl includes C 3-6 , C 3-5 , C 3-4 , C 4-7 , C 4-6 , C 4-5 , C 5-7 Or C 5-6 Cycloalkyl and the like are included, which may be monovalent, divalent and polyvalent. C 3-7 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptane, and the like.

[0048] Unless otherwise defined, the term "6-membered heterocycloalkyl" by itself or in combination with other terms refers to a saturated cyclic group composed of six ring atoms, of which one, two, three, and four ring atoms are independently selected from O, S, and N heteroatoms, and the remainder are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p , p is 1 or 2. It includes monocyclic and bicyclic ring systems, where bicyclic ring systems include spiro rings, fused rings and bridged rings. Illustrative examples of 6-membered heteroaryl include, but are not limited to, tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.) or morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.).

[0049] Unless otherwise defined, as used herein, the terms "5-membered heteroaromatic ring" and "5-membered heteroaryl" may be used interchangeably, and the term "5-membered heteroaryl" refers to a monocyclic group having a conjugated π-electron system composed of ring atoms, one, two, or three of which are independently selected from O, S, and N heteroatoms, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O)). p, p is 1 or 2). The 5-membered heteroaryl is linked to the rest of the molecule through a heteroatom or a carbon atom. Illustrative examples of 5-membered heteroaryls are pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (including 1H-1,2,3-triazolyl, 2H-1,2 , 3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc., tetrazolyl, isoxazolyl (such as 3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furanyl (including 2-furanyl and 3-furanyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.).

[0050] Unless otherwise defined, C n-n+m Or C n-Cn+m includes any one specific embodiment of n to n+m carbons, for example, C 1-12 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , and C 12 Including any one of the ranges of n to n+m, for example, C 1-12 is C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C 6-9 , C 6-12 , and C 9-12Similarly, n-membered to n+m-membered indicates that the number of atoms in the ring is n to n+m, and for example, a 3- to 12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any one of the ranges of n to n+m, and for example, a 3- to 12-membered ring includes a 3- to 6-membered ring, a 3- to 9-membered ring, a 5- to 6-membered ring, a 5- to 7-membered ring, a 6- to 7-membered ring, a 6- to 8-membered ring, and a 6- to 10-membered ring, etc.

[0051] Unless otherwise specified, when a group has one or more bondable sites, any one or more sites of the group can be bonded to other groups by chemical bonds. When the bonding mode of the chemical bond is delocalized and there is an H atom at the bondable site, the number of H atoms at the site is reduced to a group with a corresponding valence according to the number of bonded chemical bonds. The chemical bond by which the site is bonded to another group is: [ka]

[0052] For example, the straight solid bond in -OCH3 means that the group is bonded to another group through its oxygen atom. [ka] A straight dashed bond within a group means that a nitrogen atom within the group is bonded at both ends to other groups.

[0053] [ka] The wavy line in the middle means that the phenyl group is bonded to another group via carbon atoms at positions 1 and 2.

[0054] [ka] means that any available site on the naphthalene ring can be bonded to another group by one chemical bond, and at least [ka] It includes six types of bonding forms.

[0055] The compounds of the present invention can be prepared by various synthetic methods familiar to those skilled in the art, including the specific embodiments given below, embodiments in combination with other chemical synthetic methods, and equivalent alternative methods familiar to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention.

[0056] The structure of the compound of the present invention can be confirmed by conventional methods known to those skilled in the art, and when the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means of those skilled in the art. For example, single crystal X-ray diffraction (SXRD), the cultured single crystal is collected by Bruker D8 venture diffractometer, the light source is CuKα radiation, the scanning method is φ / ω scanning, after collecting the relevant data, the absolute configuration can be confirmed by direct method (Shelxs97) crystal structure analysis.

[0057] All solvents used in the present invention can be obtained from commercial sources. The present invention uses the following abbreviations: aq stands for water; eq stands for equivalent; CDI stands for carbonyldiimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DMF stands for N,N-dimethylformamide; DMSO stands for dimethylsulfoxide; EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; BOC stands for tert-butoxycarbonyl, an amine protecting group; rt stands for room temperature; O / N stands for overnight run; THF stands for tetrahydrofuran; Boc2O stands for di-tert-butyl dicarbonate; M stands for mol / L; HPLC stands for high performance liquid chromatography.

[0058] Compounds were named according to art-conventional names or ChemDraw® software; for commercially available compounds, manufacturer's catalog names were used. Effect of the Invention

[0059] The compound of the present invention has excellent AR protein degradation effect, cell proliferation inhibitory effect, and tumor suppressing effect. [Brief description of the drawings]

[0060] [Figure 1] AR proteolytic activity of enzalutamide and WX001 in the cell line LNCaP. [Diagram 2] AR proteolytic activity of WX002 in the cell line LNCaP. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0061] The present invention will be specifically described below by way of examples, but is not intended to be an adverse restriction of the present invention. The present invention has been described in detail herein, and specific embodiments thereof have been disclosed. It is obvious to those skilled in the art that various changes and modifications can be made in the specific embodiments of the present invention without departing from the spirit and scope of the present invention.

[0062] Reference Example 1 [ka] Synthesis scheme: [ka]

[0063] Step 1: Synthesis of intermediate BB-1-2 Compound BB-1-1 (1 g, 3.53 mmol) and tert-butyl carbamate (2.07 g, 17.66 mmol) were added to toluene (15 mL) and water (1.5 mL), and tris(dibenzylideneacetone)dipalladium (226.41 mg, 247.25 μmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (209.98 mg, 494.49 μmol), and potassium phosphate (3.00 g, 14.13 mmol) were added slowly to the reaction system in sequence, and the mixture was replaced with nitrogen gas three times, then heated to 100 ° C and stirred for 12 hours. The reaction solution was cooled to room temperature, and most of the organic solvent was spun off under reduced pressure. It was diluted with ethyl acetate (30 mL), and the organic phase was washed twice with water (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate=1 / 0 to 3 / 2, volume ratio) to obtain intermediate BB-1-2. 1 H NMR(400MHz, CDCl3)δ:7.83 - 7.73(m, 1H), 7.57(s, 1H), 7.47 - 7.40(m, 1H), 7.14 - 7.05(m, 1H), 6.81(br d, J=1.0 Hz, 1H), 4.19(q, J=7.0 Hz, 2H), 3.67(d, J=1.3 Hz, 2H), 1.49 - 1.42(m, 9H), 1.32 - 1.23(m, 3H).

[0064] Step 2: Synthesis of intermediate BB-1-3 At 0°C, compound BB-1-2 (300 mg, 939.40 μmol) and acrylamide (73.45 mg, 1.03 mmol, 71.31 μL) were added to tetrahydrofuran (5 mL), potassium tert-butoxide (158.12 mg, 1.41 mmol) was slowly added to the reaction, and the mixture was purged with nitrogen gas three times, then stirred at 0°C for 1 hour. The reaction solution was slowly added to saturated aqueous ammonium chloride solution (20 mL), extracted twice with ethyl acetate (20 mL x 2), the organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure. The resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 to 3 / 1, volume ratio) to obtain intermediate BB-1-3.

[0065] Step 3: Synthesis of the hydrochloride salt of intermediate BB-1 Compound BB-1-3 (40 mg, 116.16 μmol) was added to ethyl acetate (2 mL), and hydrochloric acid / dioxane (4 M, 1 mL) was slowly added dropwise to the reaction system. The mixture was purged with nitrogen gas three times, and then stirred at 25° C. for 12 hours. The reaction solution was directly spin-dried to obtain the hydrochloride salt of intermediate BB-1.

[0066] Reference Example 2 [ka] Synthesis scheme: [ka]

[0067] Step 1: Synthesis of intermediate BB-2-2 At room temperature and under nitrogen gas protection, intermediate BB-2-1 (4 g, 14.13 mmol) and tert-butyl carbamate (4.97 g, 42.39 mmol) were added to a mixture of toluene (70 mL) and water (10 mL), then potassium phosphate (12.00 g, 56.51 mmol), tris(dibenzylideneacetone)dipalladium (905.63 mg, 988.99 μmol) and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (839.93 mg, 1.98 mmol) were added in sequence, and the reaction mixture was stirred at 110 ° C. and under nitrogen gas protection for 12 hours to react. After the reaction was completed, it was cooled to room temperature, filtered through diatomaceous earth, water (100 mL) was added to the filtrate, and extracted with ethyl acetate (500 mL × 2). The organic phases were combined, washed with saturated brine (300 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent, and the resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 0 / 1 to 10 / 1, volume ratio) to obtain intermediate BB-2-2. 1 H NMR(400 MHz, CDCl3)δ: 7.71(br s, 1H), 7.63(s, 1H), 7.37(d, J=8.8 Hz, 1H), 7.14(dd, J=2.0, 8.8 Hz, 1H), 6.59(br s, 1H), 4.20(q, J=7.2 Hz, 2H), 3.67(d, J=0.8 Hz, 2H), 1.53(s, 9H), 1.29 (t, J=7.2 Hz, 3H).

[0068] Step 2: Synthesis of intermediate BB-2-3 Compound BB-2-2 (0.75 g, 1.69 mmol) and potassium tert-butoxide (284.42 mg, 2.53 mmol) were added to tetrahydrofuran (8 mL), acrylamide (312.60 mg, 2.03 mmol) was slowly added to the reaction solution, and the mixture was replaced with nitrogen gas three times, and then stirred at 0-5 ° C for 2 hours. After the reaction was completed, the reaction solution was slowly added to a saturated aqueous ammonium chloride solution (20 mL), extracted twice with ethyl acetate (20 mL × 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure, and the obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 ~ 1 / 1, volume ratio) to obtain intermediate BB-2-3. MS-ESI m / z: 245.0 [M + H] + . 1 H NMR (400MHz, CDCl3) δ: 8.13 (br s, 1H), 7.65 (br s, 1H), 7.46 (s, 1H), 7.32 (d, J=8.8 Hz, 1H), 7.04 (dd, J=2.1, 8.8 Hz, 1H), 6.57 (br s, 1H), 3.91 (t, J=7.6 Hz, 1H), 2.80 - 2.53 (m, 2H), 2.35 - 2.20 (m, 2H), 1.45 (s, 9H).

[0069] Step 3: Synthesis of the hydrochloride salt of intermediate BB-2 At room temperature, intermediate BB-2-3 (300 mg, 871.18 μmol) was dissolved in hydrochloric acid / ethyl acetate solution (4 M, 5 mL), and the reaction mixture was stirred at room temperature for 2 hours to react. After completion of the reaction, the reaction solution was concentrated under reduced pressure to remove the solvent to obtain the hydrochloride salt of intermediate BB-2. 1H NMR (400MHz, DMSO-d6) δ: 10.97 (s, 1H), 10.34 (br s, 2H), 8.05 (s, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.58 (d, J=2.0 Hz, 1H), 7.35 (dd, J=2.1, 8.7 Hz, 1H), 4.20 (dd, J=4.8, 12.3 Hz, 1H), 2.88 - 2.73 (m, 1H), 2.68 - 2.58 (m, 1H), 2.30 (dq, J=4.4, 12.6 Hz, 1H), 2.20 - 2.10 (m, 1H).

[0070] Reference Example 3 [ka]

[0071] Synthesis scheme: [ka]

[0072] Step 1: Synthesis of intermediate BB-3-2 At room temperature and under the protection of nitrogen gas, concentrated sulfuric acid (220.80 g, 2.21 mol, 120 mL, purity: 98%) was added dropwise to ice water (40 mL), then compound BB-3-1 (10 g, 44.83 mmol) was added, cooled to 5-10 ° C, ethyl 4-chloroacetoacetate (7.38 g, 44.83 mmol) was slowly added dropwise, the reaction mixture was warmed to room temperature, stirred for 16 hours, and further warmed to 50 ° C, and continued to stir for 16 hours. After the reaction was completed, it was cooled to room temperature and poured into ice water (1 L), a large amount of solid was precipitated, filtered, and the cake was collected. Toluene (400 mL) was added to the obtained solid, the solvent was removed under reduced pressure, and further toluene (400 mL) was added, and the solvent was removed again under reduced pressure to obtain intermediate BB-3-2.

[0073] Step 2: Synthesis of intermediate BB-3-3 At room temperature and under the protection of nitrogen gas, intermediate BB-3-2 (14.5 g, 44.81 mmol) was dissolved in a solution of sodium hydroxide (8.70 g, 217.52 mmol) in water (150 mL), and the reaction mixture was heated to 80° C. and stirred for 5 hours. After the reaction was completed, it was cooled to room temperature, diluted with dichloromethane (150 mL), and the organic phase was collected after separation, and the aqueous phase was extracted with dichloromethane (150 mL×3). The aqueous phase was adjusted to pH 4 with 2M dilute hydrochloric acid and extracted with ethyl acetate (200 mL×3). The organic phases were combined, washed with saturated brine (50 mL×2), dried over anhydrous sodium sulfate, filtered, the filtrate was reduced pressure, and the solvent was removed to obtain intermediate BB-3-3.

[0074] Step 3: Synthesis of intermediate BB-3-4 At room temperature and under the protection of nitrogen gas, intermediate BB-3-3 (11.3 g, 37.03 mmol) was dissolved in ethanol (300 mL), then concentrated sulfuric acid (2.08 g, 20.78 mmol, 1.13 mL, purity: 98%) was added, and the reaction mixture was heated to 80 ° C. and stirred for 12 hours to react. After the reaction was completed, it was cooled to room temperature, concentrated under reduced pressure to remove the solvent, added water (150 mL), and extracted with ethyl acetate (150 mL x 1, 100 mL x 3). The organic phases were combined, washed with saturated saline (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 to 97 / 3, volume ratio) to obtain intermediate BB-3-4. 1 H NMR(400 MHz, DMSO-d6)δ: 8.35(d, J=2.0 Hz, 1H), 8.09(t, J=4.4 Hz, 2H), 7.86(s, 2H), 7.73(dd, J=2.0, 8.8 Hz, 1H), 4.18-4.09(m, 4H), 1.18(t, J=7.2 Hz, 3H).

[0075] Step 4: Synthesis of intermediate BB-3-5 At room temperature, intermediate BB-3-4 (2.00 g, 6.00 mmol) was dissolved in toluene (60 mL) and water (6 mL) under stirring conditions, and then tert-butyl carbamate (3.52 g, 30.01 mmol), tris(dibenzylideneacetone)dipalladium (384.78 mg, 420.20 μmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (356.87 mg, 840.40 μmol), and potassium phosphate (5.10 g, 20.01 mmol) were added in sequence. The reaction mixture was replaced with nitrogen gas three times, slowly heated to 105 ° C, and reacted for 12 hours under nitrogen gas protection conditions. After the reaction was completed, it was cooled to room temperature, water (50 mL) was added to the resulting reaction solution, and it was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed successively with saturated saline (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The resulting residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 5 / 1, volume ratio) to obtain intermediate BB-3-5.

[0076] Step 5: Synthesis of intermediate BB-3-6 At 0°C and under the protection of nitrogen gas, BB-3-5 (4.00 g, 10.83 mmol) was dissolved in N,N-dimethylformamide (60 mL) solvent, to which potassium tert-butoxide (1.22 g, 10.83 mmol) and acrylamide (1.67 g, 10.83 mmol) were added, and the reaction mixture was stirred at 0°C for 3 hours to react. After the reaction was completed, water (50 mL) was added to the reaction solution, extracted with ethyl acetate (100 mL x 3), the organic phases were combined, washed sequentially with saturated saline (30 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1 to 1 / 1, volume ratio) to obtain intermediate BB-3-6. MS-ESI m / z: 338.4 [M+H] + . 1H NMR(400 MHz, DMSO-d6)δ: 10.95(s, 1H), 9.55(s, 1H), 8.25(s, 1H), 7.96(d, J=4.0 Hz, 2H), 7.72(s, 2H), 2.89(s, 3H), 2.74(s, 2H), 1.52(s, 9H).

[0077] Step 6: Synthesis of the hydrochloride salt of intermediate BB-3 BB-3-6 (1.0 g, 2.54 mmol) was dissolved in ethyl acetate (20 mL) at 0°C, hydrogen chloride·ethyl acetate (2.54 mL) was slowly added thereto, and the reaction mixture was stirred for 4 hours under nitrogen gas atmosphere. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain the hydrochloride salt of BB-3. MS-ESI m / z: 294.31 [M+H] + .

[0078] Reference Example 4 [ka]

[0079] Synthesis scheme: [ka]

[0080] Step 1: Synthesis of intermediate BB-4-2 At 0-5°C and under the protection of nitrogen gas, compound BB-4-1 (10 g, 78.67 mmol) was dissolved in dichloromethane (120 mL) and acetone (60 mL), and then cyanotrimethylsilane (12.45 g, 125.50 mmol, 15.70 mL) and trimethylsilyl trifluoromethanesulfonate (820.00 mg, 3.69 mmol, 666.67 μL) were added dropwise slowly, and the reaction mixture was stirred at 25°C for 2 hours. After the reaction was completed, the mixture was cooled to 0-5°C, diluted with water (200 mL), and extracted with ethyl acetate (200 mL x 3). The combined organic phase was washed with saturated saline (100 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was subjected to reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 5 / 1, volume ratio) to obtain compound BB-4-2. H NMR (400MHz, CDCl3) δ: 6.83 (t, J = 9.0 Hz, 1H), 6.74 (dd, J = 2.7, 12.1 Hz, 1H), 6.66 - 6.59 (m, 1H), 1.65 (s, 6H).

[0081] Step 2: Synthesis of chemical BB-4-3 At room temperature and under the protection of nitrogen gas, compound BB-4-2 (8 g, 45.40 mmol) was dissolved in N,N-dimethylacetamide (150 mL), 4-isothiocyanato-2-(trifluoromethyl)benzonitrol (10.36 g, 45.40 mmol) was added to the reaction solution in batches, the reaction mixture was stirred at 25 ° C for 12 hours, methanol (60 mL), dilute hydrochloric acid (2 M, 60 mL) were added, the reaction mixture was stirred at 70 ° C for 3 hours, after the reaction was completed, it was cooled to room temperature, diluted by adding water (500 mL), and extracted with ethyl acetate (200 mL × 3). The organic phases were combined, washed with saturated saline (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1 to 1 / 1, volume ratio) to obtain compound BB-4-3. 1H NMR(400MHz, CDCl3)δ:8.03 - 7.94(m, 1H), 8.02 - 7.94(m, 1H), 8.05 - 7.92(m, 1H), 8.04 - 7.92(m, 1H), 8.15 - 7.89(m, 1H), 7.86(d, J=1.5 Hz, 1H), 7.82 - 7.79(m, 1H), 7.19 - 7.10(m, 2H), 6.99 - 6.90(m, 2H), 6.06(br s, 1H), 1.58(s, 6H).

[0082] Step 3: Synthesis of chemical BB-4-4 At room temperature and under the protection of nitrogen gas, compound BB-4-3 (2 g, 4.72 mmol) was dissolved in N,N-dimethylformamide (50 mL), and tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (1.66 g, 5.67 mmol), potassium carbonate (1.31 g, 9.45 mmol), and potassium iodide (784.17 mg, 4.72 mmol) were added in sequence, and the reaction mixture was heated to 80 ° C. and stirred for 12 hours to react. After the reaction was completed, it was cooled to room temperature, diluted by adding water (100 mL), and extracted with ethyl acetate (100 mL × 3). The organic phases were combined, washed with saturated saline (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1 to 1 / 1, volume ratio) to obtain compound BB-4-4. MS-ESI m / z: 636.3 [M+H] + .

[0083] Step 4: Synthesis of the hydrochloride salt of compound BB-4-5 At room temperature and under the protection of nitrogen gas, compound BB-4-4 (2.0 g, 3.15 mmol) was dissolved in ethyl acetate (50 mL), hydrogen chloride·ethyl acetate (4 M, 3.93 mL) was slowly added dropwise to the reaction mixture, the reaction mixture was stirred at 25° C. for 12 hours, and after the reaction was completed, the reaction mixture was concentrated under reduced pressure to obtain the hydrochloride salt of compound BB-4-5. 1H NMR(400MHz, CD3OD)δ: 8.23 ​​- 8.13(m, 2H), 8.00(dd, J=1.8, 8.3 Hz, 1H), 7.40(t, J=8.9 Hz, 1H), 7.32(dd, J=2.4, 11.4 Hz, 1H), 7.24(br d, J=8.8 Hz, 1H), 4.69 - 4.60(m, 2H), 3.88 - 3.79(m, 6H), 3.75 - 3.65(m, 4H), 1.58(s, 6H).

[0084] Step 5: Synthesis of chemical BB-4-6 At room temperature and under the protection of nitrogen gas, compound BB-4-5 (1.5 g, 2.62 mmol, hydrochloride salt) was dissolved in acetonitrile (50 mL), and then ethyl bromoacetate (875.85 mg, 5.24 mmol, 580.04 μL) and potassium carbonate (724.86 mg, 5.24 mmol) were added in sequence, and the reaction mixture was heated to 80 ° C. and reacted with stirring for 5 hours. After the reaction was completed, it was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (100 mL × 3). The organic phases were combined, washed with saturated saline (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1 to 1 / 1, volume ratio) to obtain compound BB-4-6. MS-ESI m / z: 622.2 [M + H] + .

[0085] Step 6: Synthesis of compound BB-4 At room temperature and under the protection of nitrogen gas, compound BB-4-6 (1.5 g, 2.42 mmol) was dissolved in ethanol (50 mL), lithium hydroxide (1 M, 7.25 mL) was slowly added dropwise to the reaction mixture, and the reaction mixture was stirred at 25 °C for 12 hours. After the reaction was completed, the reaction mixture was adjusted to pH = 2-3 with 2 M hydrochloric acid, and the reaction mixture was concentrated under reduced pressure to obtain compound BB-4. MS-ESI m / z: 594.1 [M+H] + .

[0086] Reference Example 5 [ka]

[0087] Synthesis scheme: [ka]

[0088] Compound BB-1-1 (3 g, 10.60 mmol) and allyl alcohol (1.34 g, 23.07 mmol, 1.57 mL) were added to dioxane (30 mL), and N-cyclohexyl-N-methyl-cyclohexylamine (2.48 g, 12.72 mmol, 2.70 mL), tri-tert-butylphosphine (4.29 g, 2.12 mmol, 4.97 mL, content: 10%) and tris(dibenzylideneacetone)dipalladium (970.32 mg, 1.06 mmol) were slowly added to the reaction system. The mixture was replaced with nitrogen gas three times and then stirred at 30 ° C for 12 hours. Water (50 mL) was slowly added to the reaction solution, and the organic phase was extracted three times with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate=0 / 1 to 3 / 1, volume ratio) to obtain compound BB-5. 1 H NMR(400MHz, CDCl3)δ: 9.84(s, 1H), 7.60(s, 1H), 7.50(d, J=8.0 Hz, 1H), 7.33(s, 1H), 7.12(dd, J=1.0, 8.0 Hz, 1H), 4.24 - 4.16(m, 2H), 3.69(d, J=0.8 Hz, 2H), 3.14 - 3.03(m, 2H), 2.90 - 2.78(m, 2H), 1.29(t, J=7.2 Hz, 3H).

[0089] Reference Example 6 [ka] Synthesis scheme: [ka]

[0090] Step 1: Synthesis of intermediate BB-6-2 At 25°C, compound 1-aminocyclopropane-1-carboxylate ethyl hydrochloride (1.0g, 6.04mmol) was added to ethanol (10mL), stirring was started, and compound N-benzyl-2-chloro-N-(2-chloroethyl)ethylamine hydrochloride (1.78g, 6.64mmol) and N,N-diisopropylethylamine (7.88g, 60.98mmol, 10.62mL) were added in sequence. Under the protection of nitrogen gas, the mixture was heated to 80°C, and stirring was continued for 12 hours under the protection of nitrogen gas. After the reaction was completed, the reaction solution was cooled to room temperature, and then directly spin-dried, and the crude product was added with water (20mL) and extracted with ethyl acetate (20mL x 2). The organic phases were combined and washed with half-saturated saline (10 mL × 2). Anhydrous sodium sulfate was added to the organic phase, dried, and then filtered. The filtrate was concentrated under reduced pressure to remove the solvent, and the resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1 to 1 / 1, volume ratio) to obtain intermediate BB-6-2. 1 H NMR (400 MHz, CDCl3) δ:7.40-7.27 (m, 5 H), 4.18 (q, J=7.20 Hz, 2H), 3.55 (s, 2H), 3.02 ( s, 4H), 2.40 ( s, 4H), 1.28-1.34 (m, 5H), 0.94 (q, J=3.6 Hz, 2H).

[0091] Step 2: Synthesis of intermediate BB-6-3 At 25°C, intermediate BB-6-2 (0.3g, 1.04mmol) was added to ethanol (20mL), stirring was started, and compound potassium hydroxide (583.66mg, 10.40mmol) was added in sequence, heated to 120°C, and stirring was continued for 12 hours. After the reaction was completed, the reaction solution was cooled to room temperature and spin-dried. Then, water (40mL) was added, and extracted with ethyl acetate (40mL x 2). 4M dilute hydrochloric acid was added to the aqueous phase to adjust the pH to 3, and then ethyl acetate (40mL) was added for extraction, the product was in the aqueous phase, and the aqueous phase was collected and lyophilized. Compound BB-6-3 was obtained. 1 H NMR (400 MHz, DMSO-d6) δ: 10.70 ( s, 1H), 7.59 ( s, 2H), 7.45 (s, 3H), 4.26 ( s, 2H),3.46 (t, J=12.4 Hz, 2H),3.21 ( d, J=11.6 Hz, 2H),2.94 (d, J=12.8 Hz, 2H),2.83 (s, 2H),1.16 (s, 2H),0.94 (s, 2H).

[0092] Step 3: Synthesis of chemical BB-6-4 At 25° C., intermediate BB-6-3 was added to N,N-dimethylformamide (20 mL), stirring was started, and compound BB-2 (938.21 mg, 3.84 mmol), 2-(7-azabenzotriazole)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (2.19 g, 5.76 mmol), and triethylamine (1.55 g, 15.37 mmol, 2.14 mL) were added in sequence. Stirring was continued for 12 hours under the protection of nitrogen gas. After the reaction was completed, water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined and washed with half-saturated saline (50 mL). Anhydrous sodium sulfate was added to the organic phase, and the mixture was dried and then filtered. The filtrate was concentrated under reduced pressure to remove the solvent, and the resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to 0 / 1, volume ratio) to obtain intermediate BB-6-4. MS-ESI m / z:: 487.2 [M+H] + . 1H NMR (400 MHz, DMSO-d6) δ:10.91 (s, 1H), 9.92 (s, 1H), 7.95 (s, 1H), 7.88 (s, 1H), 7.53 (d, J=8.8Hz, 1H), 7.41 (dd, J=8.8, 1.6Hz, 1H), 7.35-7.28 (m, 4H), 7.27-7.22 (m, 1H), 4.12 (dd, J=12.0, 4.8Hz, 1H), 3.50 (s, 2H), 3.40-3.30 (m, 2H), 2.89 (s, 2H), 2.83-2.74(m, 1H), 2.73 (s, 2H), 2.61-2.60 (m, 1H), 2.56-2.55 (m, 2H), 2.34-2.20 (m, 1H), 2.14-2.10 (m, 1H),1.08 - 1.06( m, 4H).

[0093] Step 4: Synthesis of compound BB-6 Compound BB-6-4 (50 mg, 97.91 μmol) was dissolved in tetrahydrofuran (10 mL) at 25° C., and under the protection of argon gas, wet palladium carbon (5 mg, 10.28 μL) was added, and the mixture was replaced with hydrogen gas three times, the pressure was maintained at 40 Psi, and the reaction solution was heated to 30° C. and stirred in a hydrogen gas atmosphere for 12 hours. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain compound BB-6. MS-ESI m / z: 397.1 [M+H] + .

[0094] Reference Example 7 [ka] Synthesis scheme: [ka]

[0095] Step 1: Synthesis of chemical BB-7-2 Compound triphenyl phosphite (48.42 g, 156.06 mmol, 41.04 mL) was dissolved in dichloromethane (250 mL) at 25 ° C., cooled to -70 ° C. in a nitrogen gas atmosphere, liquid bromine (27.21 g, 170.25 mmol, 8.78 mL) was added dropwise, and after completion of the addition, triethylamine (18.66 g, 184.44 mmol, 25.67 mL) and compound BB-7-1 (25.00 g, 141.88 mmol) in dichloromethane (60 mL) were added dropwise, and after completion of the addition, the temperature was slowly raised to 25 ° C. and stirred for 12 hours. After the reaction was completed, the reaction solution was slowly poured into saturated aqueous sodium sulfite solution (400 mL), stirred for 10 minutes, extracted with dichloromethane (200 mL x 3), and the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (eluent: pure petroleum ether). Compound BB-7-2 was obtained. 1 H NMR (400MHz, CDCl3) δ: 7.48 (d, J=8.78 Hz, 1H), 6.75 (dd, J=8.53, 2.51 Hz, 1H), 6.68 (d, J=2.76 Hz, 1H), 6.30 (t, J=4.77 Hz, 1H), 3.82 (s, 3H), 2.82 (t, J= 8.03Hz, 2H), 2.35 (td, J=8.03, 5.02 Hz, 2H).

[0096] Step 2: Synthesis of chemical BB-7-3 Compound BB-7-2 (10.00 g, 41.82 mmol) was dissolved in toluene (100 mL) at 25 ° C., cooled to 0 ° C. under the protection of nitrogen gas, and dichlorodicyanobenzoquinone (10.44 g, 46.00 mmol) was added in batches. After the addition was completed, the mixture was reacted at 25 ° C. for 15 hours. Saturated aqueous sodium sulfite solution (200 mL) was added dropwise to the reaction solution to quench the reaction system, and after stirring for 10 minutes, 1N aqueous sodium hydroxide solution (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3), the organic phase was washed with saturated saline solution (100 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The obtained crude product was slurried in petroleum ether (50 mL) for 10 minutes, filtered, the cake was rinsed with petroleum ether (25 mL × 2), the filtrate was spin-dried, and the crude product was purified by column chromatography (eluent: pure petroleum ether). Compound BB-7-3 was obtained. 1 H NMR (400MHz, CDCl3) δ: 8.13 (d, J=9.29 Hz, 1H), 7.67 (d, J=8.28 Hz, 1H), 7.61 (d, J=7.28 Hz, 1H), 7.21-7.26 (m, 2H), 7.11 (d, J=2.51 Hz, 1H), 3.92 (s, 3H).

[0097] Step 3: Synthesis of chemical BB-7-4 Compound BB-7-3 (4.90 g, 20.67 mmol) was dissolved in dichloromethane (50 mL) at 25 ° C., cooled to 0 ° C., and boron tribromide (6.21 g, 24.80 mmol, 2.39 mL) was slowly added dropwise. After completion of the addition, the mixture was stirred at 25 ° C. for 3 hours. The reaction solution was poured into ice water (250 mL) to quench the reaction system, extracted with dichloromethane (100 mL), and the organic phase was washed with saturated saline (100 mL × 1), dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound BB-7-4 was obtained. 1H NMR (400MHz, CDCl3) δ: 8.19 (d, J=9.03 Hz, 1H), 7.63-7.73 (m, 2H), 7.26-7.32 (m, 1H), 7.23 (dd, J=9.03, 2.51 Hz, 1H), 7.19 (d, J=2.51 Hz, 1H).

[0098] Step 4: Synthesis of chemical BB-7-5 Compound BB-7-4 (2.50 g, 11.21 mmol) was dissolved in methanesulfonic acid (25 mL) at 20° C., and ethyl 4-chloroacetoacetate (2.77 g, 16.81 mmol, 2.27 mL) was added dropwise and stirred at 20° C. for 15 hours. The reaction solution was quenched by pouring into ice water (200 mL), stirred for 10 minutes, filtered, and the cake was rinsed with water (30 mL×3), then spin-dried. Compound BB-7-5 was obtained. 1 H NMR (400 MHz, DMSO-d6) δ: 8.56 (d, J=8.78 Hz, 1H), 8.46 (d, J=9.29 Hz, 1 H), 7.71 (d, J=9.29 Hz, 1H), 7.63 (dd, J=8.66, 7.65 Hz, 1H), 6.92 (s, 1H), 5.39 (s, 2H).

[0099] Step 5: Synthesis of chemical BB-7-6 Compound BB-7-5 (0.10 g, 309.05 μmol) was added to an aqueous solution of sodium hydroxide (2 M, 1.03 mL) at 25° C. and stirred at 80° C. for 3 hours. The reaction solution was cooled to 25° C., diluted with water (10 mL), adjusted to pH=3 with dilute hydrochloric acid (2 M, aqueous solution), extracted with ethyl acetate (10 mL×3), the organic phase was washed with saturated saline (10 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried. Compound BB-7-6 was obtained. 1H NMR (400 MHz, DMSO-d6) δ: 12.59 (br s, 1H), 8.24 (d, J=8.38 Hz, 1H), 7.96 (d, J=9.26 Hz, 1H), 7.90 (d, J=7.50 Hz, 1H), 7.54 (dd, J=2.8 Hz, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 4.08 (s, 2H).

[0100] Step 6: Synthesis of compound BB-7 Compound BB-7-6 (1.40 g, 4.59 mmol) was dissolved in anhydrous ethanol (14 mL) at 25 ° C., and sulfuric acid (413.28 mg, 4.13 mmol, 224.61 μL, 98% concentration) was slowly added dropwise, and then the temperature was raised to 80 ° C. and stirred for 12 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and ethyl acetate (60 mL) was added to dilute it, a saturated aqueous solution of sodium bicarbonate (60 mL) was added, and it was extracted with ethyl acetate (60 mL × 2), and the organic phase was washed with saturated saline (60 mL × 1), dried with anhydrous sodium sulfate, filtered, and spin-dried. Petroleum ether (5 mL) was added, and the mixture was slurried at room temperature, stirred for 10 minutes, and then filtered, and the cake was rinsed with petroleum ether (5 mL × 2), and the cake was collected and spin-dried. Compound BB-7 was obtained. 1 H NMR (400MHz, CDCl3) δ: 8.22 (t, J=8.41Hz, 2H), 7.78-7.85 (m, 2H), 7.75 (d, J=9.29Hz, 1H), 7.41 (t, J=7.91Hz, 1H), 4.23 (q, J=7.03 Hz, 2H), 4.06 (s, 2H), 1.26 (t, J=7.15Hz, 3H).

[0101] Reference Example 8 [ka] Synthesis scheme: [ka]

[0102] Step 1: Synthesis of compound 8-1 Compound BB-7 (5 g, 15.01 mmol) was dissolved in a mixed solvent of toluene (50 mL) and water (10 mL), and tert-butyl carbamate (2.64 g, 22.51 mmol), potassium phosphate (12.74 g, 60.03 mmol), tris(dibenzylideneacetone)dipalladium (961.96 mg, 1.05 mmol) and 2-di-tert-butylphosphino-2,4,6-triisopropylbiphenyl (892.16 mg, 2.10 mmol) were added, and the mixture was replaced with nitrogen gas three times, and the temperature was raised to 100 ° C. and stirred for 15 hours. The reaction solution was cooled to room temperature, filtered, the cake was rinsed with ethyl acetate (30 mL × 3), and the filtrate was washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was added with methyl tert-butyl ether (50 mL), stirred for 10 min, filtered, the cake was rinsed with methyl tert-butyl ether (10 mL×2), and the cake was collected to give compound BB-8-1.

[0103] Step 2: Synthesis of chemical BB-8-2 Compound BB-8-1 (4.2 g, 11.37 mmol) and acrylamide (888.93 mg, 12.51 mmol, 863.04 μL) were dissolved in N,N-dimethylformamide (40 mL) and cooled to 0 ° C under nitrogen gas protection, potassium tert-butoxide (2.55 g, 22.74 mmol) in N,N-dimethylformamide (10 mL) was added dropwise, and the mixture was heated to 20 ° C and stirred for 2 hours. The reaction solution was poured into 0.2 N dilute hydrochloric acid (200 mL), extracted with ethyl acetate (100 mL × 3), the organic phase was washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. Dichloromethane (20 mL) was added to the crude product, stirred for 10 minutes, filtered, the cake was rinsed with dichloromethane (10 mL), and the cake was collected to obtain compound BB-8-2. 1H NMR (400 MHz, DMSO-d6) δ:10.94 (s, 1H), 9.28 (s, 1H), 8.04-7.96 (m, 3H), 7.79 (d, J=9.6 Hz, 1H), 7.55-7.51 (m, 2H), 4.67 (dd, J=4.4 Hz, 12.0 Hz, 1H), 2.93-2.84 (m, 1H), 2.66-2.60 (m, 1H), 2.45-2.36 (m, 1H), 2.33-2.26 (m, 1H), 1.49 (s, 9H).

[0104] Step 3: Synthesis of the hydrochloride salt of compound BB-8 Compound BB-8-2 (1 g, 2.54 mmol) was dissolved in ethyl acetate (10 mL), and hydrogen chloride-ethyl acetate (4 M, 50.00 mL) was added dropwise and stirred at 20° C. for 15 hours. The reaction solution was concentrated under reduced pressure to obtain the hydrochloride salt of compound BB-8.

[0105] Reference Example 9 [ka] Synthesis scheme: [ka]

[0106] Step 1: Synthesis of chemical BB-9-1 Compound BB-4-3 (13 g, 30.71 mmol) and potassium carbonate (8.49 g, 61.41 mmol) were dissolved in N,N-dimethylformamide (300 mL), 1,2-dibromoethane (28.84 g, 153.53 mmol, 11.58 mL) was added, and the mixture was heated to 80 ° C. and stirred for 12 hours. The reaction solution was cooled to room temperature, water (1 L) was added, and the mixture was extracted with ethyl acetate (300 mL × 3), and the organic phase was washed with saturated saline (300 mL × 2), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain compound BB-9-1. 1H NMR (400MHz, CDCl3) δ: 8.00-7.96 (m, 2H), 7.85-7.83 (m, 1H), 7.14-7.04 (m, 3H), 4.44 (t, J=6.0 Hz, 2H), 3.71 (t, J=6.4 Hz, 2H), 1.60 (s, 6H).

[0107] Step 2: Synthesis of chemical BB-9 Compound BB-9-1 (3 g, 5.66 mmol) and methylamine hydrochloride (1.91 g, 28.28 mmol) were added to N,N-dimethylformamide (30 mL), potassium carbonate (11.73 g, 84.85 mmol) was added, and the mixture was heated to 50 ° C and stirred for 12 hours. The reaction solution was cooled to room temperature, water (70 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 4), and the organic phase was washed with saturated saline (70 mL × 2), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: dichloromethane / methanol = 50 / 1 to 10 / 1) to obtain compound BB-9.

[0108] Reference Example 10: Fragment BB-10: [ka] Synthesis scheme: [ka]

[0109] Step 1: Synthesis of compound BB-10-2 At 0°C and under the protection of nitrogen gas, compound BB-10-1 (5g, 18.03mmol) was dissolved in dichloromethane (50mL) and acetone (25mL), and then cyanotrimethylsilane (2.68g, 27.04mmol, 3.38mL) and trimethylsilyl trifluoromethanesulfonate (400.67mg, 1.80mmol, 325.74μL) were added dropwise slowly, and the reaction mixture was stirred at 20°C for 2 hours. After the reaction was completed, the reaction solution was decompressed to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 to 4 / 1, volume ratio) to obtain compound BB-10-2.

[0110] Step 2: Synthesis of chemical BB-10 At room temperature and under the protection of nitrogen gas, compound BB-10-2 (10 g, 29.03 mmol) was dissolved in N,N-dimethylacetamide (100 mL), 4-isothiocyanato-2-(trifluoromethyl)benzonitrol (6.62 g, 29.03 mmol) and added to the reaction solution in batches, the reaction mixture was stirred at 20 ° C for 3 hours, methanol (100 mL), dilute hydrochloric acid (2 M, 56.32 mL) were added, the reaction mixture was stirred at 70 ° C for 2 hours, after the reaction was completed, it was cooled to room temperature, diluted by adding water (100 mL), and extracted with ethyl acetate (100 mL × 3). The organic phases were combined, washed with saturated saline (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: dichloromethane / methanol = 20 / 1 to 10 / 1, volume ratio) to obtain compound BB-10. 1 H NMR (400 MHz, CDCl3) δ:7.99 (d, J=8.8 Hz, 1H), 7.96 (d, J=1.6 Hz, 1H), 7.84 (dd, J=2.0, 8.4 Hz, 1H), 7.22 (d, J=9.2 Hz, 2H), 7.04 (d, J=8.8 Hz, 2H), 3.64-3.57 (m, 4H), 3.45-3.38 (m, 4H), 1.58 (s, 6H).

[0111] Reference Example 11: Fragment BB-11: [ka] Synthesis scheme: [ka]

[0112] Step 1: Synthesis of chemical BB-11-2 At 0°C and under the protection of nitrogen gas, compound BB-11-1 (0.87g, 5.57mmol) and compound tert-butyl [(1R,4R)-4-hydroxycyclohexyl] carbamate (1.00g, 4.64mmol) were dissolved in N,N-dimethylformamide (20mL), then sodium hydrogen (278.68mg, 6.97mmol, 60%) was added, and the mixture was reacted by stirring at 0°C for 2 hours. After the reaction was completed, water (50mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50mL x 3). The organic phases were combined, washed successively with water (50mL x 3) and saturated saline (50mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 to 6 / 1, volume ratio) to obtain compound BB-11-2. 1 H NMR (400MHz, CDCl3) δ: 8.00 (s, 1H), 7.56-7.47 (m, 1H), 6.97-6.92 (m, 1H), 6.84-6.72 (m, 1H), 4.29-4.17 (m, 1H), 4.13-4.08 (m, 1H), 2.14-2.03 (m, 4H), 1.47-1.38 (m, 9H), 1.26-1.20 (m, 4H).

[0113] Step 2: Synthesis of the hydrochloride salt of compound BB-11-3 At room temperature, compound BB-11-2 (2.70 g, 7.70 mmol) was dissolved in methanol (5 mL), then 4M hydrogen chloride in methanol (25 mL) was added, and the reaction mixture was stirred at room temperature for 12 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to remove the solvent to obtain the hydrochloride salt of compound BB-11-3, which was directly used in the subsequent reaction.

[0114] Step 3: Synthesis of chemical BB-11-6 At room temperature, compound BB-11-5 (10.00 g, 57.95 mmol) and 4-piperidinemethanol (6.67 g, 57.95 mmol) were dissolved in dimethyl sulfoxide (100 mL), and then triethylamine (11.73 g, 115.90 mmol, 16.13 mL) was added, and the reaction mixture was heated to 90 ° C. and stirred for 12 hours to react. After the reaction was completed, it was cooled to room temperature, and water (200 mL) was added to the reaction solution, and it was extracted with dichloromethane (100 mL × 4). The organic phases were combined, washed successively with water (100 mL × 2) and saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: dichloromethane / methanol = 1 / 0 ~ 20 / 1, volume ratio) to obtain compound BB-11-6. 1 H NMR (400 MHz, DMSO-d6) δ:7.79 (d, J=9.2 Hz, 1H), 7.27 (d, J=9.6 Hz, 1H), 4.57-4.53 (m, 1H), 4.53-4.48 (m, 2H), 3.86 (s, 3H), 3.30-3.24 (m, 2H), 2.99 (td, J=1.9, 12.7 Hz, 2H), 1.81-1.66 (m, 3H), 1.21-1.06 (m, 2H).

[0115] Step 4: Synthesis of chemical BB-11-7 At room temperature, BB-11-6 (2.00 g, 7.96 mmol) was dissolved in tetrahydrofuran (15 mL), then 2 M aqueous sodium hydroxide solution (15 mL) was added, and the reaction mixture was stirred at room temperature for 12 hours to react. After the reaction was completed, the pH was adjusted to 4-5 with 4 M hydrochloric acid, and the solvent was removed by concentration under reduced pressure to obtain the crude product of compound BB-11-7, which was directly used in the subsequent reaction.

[0116] Step 5: Synthesis of chemical BB-11-4 At room temperature and under the protection of nitrogen gas, compound BB-11-3 hydrochloride (7.65 mmol) and compound BB-11-7 (7.65 mmol, crude product) were dissolved in N,N-dimethylformamide (46 mL), then diisopropylethylamine (1.03 g, 7.96 mmol, 1.39 mL) and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (3.03 g, 7.96 mmol) were added and reacted at room temperature for 12 hours with stirring. After the reaction was completed, water (100 mL) was added to the reaction solution and extracted with ethyl acetate (70 mL x 3). The organic phases were combined and washed successively with water (100 mL x 2) and saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The resulting residue was separated by column chromatography (eluent: dichloromethane / methanol = 1 / 0 to 20 / 1, volume ratio) to obtain compound BB-11-4. MS-ESI m / z: 470.2 [M+H] + . 1H NMR (400 MHz, DMSO-d6) δ: 8.58 (d, J=8.4 Hz, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.79 (d, J=9.6 Hz, 1H), 7.38 (d, J=2.4 Hz, 1H), 7.33 (d, J=9.6 Hz, 1H), 7.13 (dd, J=2.4, 8.8 Hz, 1H), 4.60-4.44 (m, 4H), 3.92-3.79 (m, 1H), 3.32-3.27 (m, 2H), 3.07-2.95 (m, 2H), 2.18-2.05 (m, 2H), 1.95-1.84 (m, 2H), 1.81-1.68 (m, 3H), 1.68-1.51 (m, 2H), 1.51-1.48 (m, 2H), 1.20-1.06 (m, 2H).

[0117] Step 6: Synthesis of chemical BB-11 At room temperature, compound BB-11-4 (100.02 mg, 205.06 μmol) was dissolved in dichloromethane (6 mL), then Dess-Martin oxidant (130.46 mg, 307.59 μmol) was added, and the mixture was stirred at room temperature for 1 hour to react. After the reaction was completed, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated saline (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 to 0 / 1, volume ratio) to obtain compound BB-11. MS-ESI m / z: 468.2 [M + H] +.

[0118] Reference Example 12: Fragment BB-12: [ka] Synthesis scheme: [ka]

[0119] Step 1: Synthesis of chemical BB-12-1 Compound BB-3-4 (10.00 g, 30.01 mmol) and 1-tert-butoxycarbonylpiperazine (8.39 g, 45.02 mmol) were added to toluene (150 mL) and water (20 mL) at 25 ° C., tris (dibenzylideneacetone) dipalladium (1.92 g, 2.10 mmol), potassium phosphate (19.11 g, 90.04 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (1.78 g, 4.20 mmol) were slowly added to the reaction system, the mixture was purged with nitrogen gas three times, and then heated to 100 ° C. and stirred for 12 hours. The reaction solution was cooled to 25 ° C., filtered through diatomaceous earth, and the cake was washed with 20 mL of ethyl acetate. The filtrate was added to 300 mL of ethyl acetate and 300 mL of water, the aqueous phase was extracted with ethyl acetate (200 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The crude product was separated by column chromatography (eluent: petroleum ether: ethyl acetate = 50 / 1 to 5 / 1) to obtain compound BB-12-1. MS-ESI m / z: 439.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ: 8.15 (d, J=9.0 Hz, 1H), 7.74 (s, 1H), 7.60 (s, 2H), 7.36 (dd, J=2.5, 9.0 Hz, 1H), 7.31 (d, J=2.5 Hz, 1H), 4.23 (q, J=7.1 Hz, 2H), 4.04 (s, 2H), 3.71 - 3.62 (m, 4H), 3.29 - 3.20 (m, 4H), 1.53 (s, 9H), 1.28 (dt, J=7.2 Hz, 3H).

[0120] Step 2: Synthesis of chemical BB-12-2 Compound BB-12-1 (8.6 g, 15.86 mmol) and acrylamide (1.13 g, 15.86 mmol, 1.09 mL) were added to N,N-dimethylformamide (80 mL) at 0 ° C., stirring was started, potassium tert-butoxide (2.67 g, 23.80 mmol) was added to the reaction system in batches, the reaction solution was replaced with nitrogen gas three times, and then stirred at 0 ° C. for 1 hour. After the reaction was completed, the reaction solution was slowly dropped into a saturated aqueous ammonium chloride solution (480 mL) to precipitate a large amount of solid, filtered, the cake was washed twice with water (20 mL × 2), the cake was collected, and spin-dried under reduced pressure. The obtained crude product was added to methanol (10 mL) and stirred for 30 minutes, filtered, the cake was washed with methanol (5 mL), the cake was collected, and spin-dried under reduced pressure to obtain compound BB-12-2. 1 H NMR (400MHz, DMSO-d6) δ: 10.96 (br dd, J=2.9, 6.1 Hz, 1H), 8.02 (br d, J=8.8 Hz, 1H), 7.97 - 7.91 (m, 1H), 7.72 - 7.65 (m, 2H), 7.44 - 7.37 (m, 2H), 4.62 (br dd, J=4.3, 11.8 Hz, 1H), 3.53 (br s, 4H), 3.22- 3.20 (m, 4H), 2.93 - 2.83 (m, 1H), 2.68 - 2.57 (m, 1H), 2.39 (dq, J=4.3, 12.5 Hz, 1H), 2.26 (br dd, J=3.9, 8.7 Hz, 1H), 1.44 (s, 9H).

[0121] Step 3: Synthesis of the hydrochloride salt of compound BB-12 Compound BB-12-2 (3.4 g, 7.34 mmol) was added to ethyl acetate (20 mL), stirring was started, and hydrogen chloride-ethyl acetate solution (4 M, 30 mL) was slowly added. The reaction solution was purged with nitrogen gas three times, and then stirred at 25° C. for 12 hours. After the reaction was completed, it was filtered, the cake was washed with ethyl acetate (5 mL × 2), the cake was collected, and spin-dried under reduced pressure to obtain the hydrochloride salt of compound BB-12. 1H NMR (400MHz, DMSO-d6) δ: 10.96 (s, 1H), 9.65 (br s, 2H), 8.07 (br d, J=9.3 Hz, 1H), 7.96 (s, 1H), 7.75 - 7.69 (m, 2H), 7.53 (d, J=2.3 Hz, 2H), 7.45 (dd, J=2.4, 9.2 Hz, 1H), 4.64 (br dd, J=4.4, 11.9 Hz, 1H), 3.54 (br d, J=5.0 Hz, 4H), 3.28 (br s, 4H), 2.94 - 2.82 (m, 1H), 2.67 - 2.58 (m, 1H), 2.39 (br dd, J=4.0, 12.5 Hz, 1H), 2.30 - 2.17 (m, 1H).

[0122] Reference example 13: Furaconto BB-13

change

change

[0123] ステップ1:Synthesis of chemical BB-13-1 Compound BB-7 (1.4 g, 4.20 mmol) and 1-tert-butoxycarbonylpiperazine (1.17 g, 6.30 mmol) were added to dioxane (20 mL) and water (4 mL) at 25 ° C., tris (dibenzylideneacetone) dipalladium (269.35 mg, 294.14 μmol), potassium phosphate (2.68 g, 12.61 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (249.81 mg, 588.28 μmol) were slowly added to the reaction system, the mixture was purged with nitrogen gas three times, and then the temperature was raised to 100 ° C. and stirred for 12 hours. The reaction solution was cooled to 25 ° C., filtered through diatomaceous earth, and the cake was washed with 20 mL of ethyl acetate. The filtrate was added to ethyl acetate (100 mL) and water (100 mL), the aqueous phase was extracted with ethyl acetate (100 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 50 / 1 to 10 / 1) to obtain compound BB-13-1. MS: ESI m / z: 439.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 8.17 (d, J=9.3 Hz, 1H), 8.04 (s, 1H), 7.86 (d, J=8.3 Hz, 1H), 7.77 (d, J=9.3 Hz, 1H), 7.53 (t, J=8.0 Hz, 1H), 7.19 (d, J=7.3 Hz, 1H), 4.20 - 4.09 (m, 4H), 3.36 - 2.59 (m, 8H), 1.45 (s, 9H), 1.20 (t, J=7.0 Hz, 3H).

[0124] Step 2: Synthesis of chemical BB-13-2 Compound BB-13-1 (1.5 g, 3.26 mmol) and acrylamide (231.68 mg, 3.26 mmol, 224.93 μL) were added to N,N-dimethylformamide (20 mL) at 0° C., stirring was started, potassium tert-butoxide (438.91 mg, 3.91 mmol) was slowly added to the reaction system in batches, the reaction solution was replaced with nitrogen gas three times, and then stirred at 0° C. for 1 hour. The mixture was slowly added dropwise to a saturated aqueous ammonium chloride solution (75 mL), a solid was precipitated, and filtered. The cake was washed with water (5 mL×2), the solid was collected, and spin-dried under reduced pressure. The crude product was added to 5 mL of methanol, stirred for 15 minutes, filtered, the cake was washed with methanol (3 mL×2), the solid was collected, and spin-dried under reduced pressure. Compound BB-13-2 was obtained. MS-ESI m / z: 464.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ:8.19 (d, J=9.3 Hz, 1H), 7.97 (d, J=16.8 Hz, 2H), 7.78 (d, J=9.0 Hz, 1H), 7.51 (br t, J=8.0 Hz, 1H), 7.18 (br d, J=7.5 Hz, 1H), 4.66 (br d, J=7.8 Hz, 1H), 3.34 (m, 4H), 3.17 (m, 4H), 2.89 - 2.81 (m, 1H), 2.68 - 2.55 (m, 1H), 2.40 (dq, J=3.8, 12.4 Hz, 1H), 2.26 (br s, 1H), 1.44 (s, 9H).

[0125] Step 3: Synthesis of the hydrochloride salt of compound BB-13 Compound BB-13-2 (0.6 g, 1.16 mmol) was added to ethyl acetate (6 mL), stirring was started, hydrogen chloride-ethyl acetate (4 M, 10 mL) was slowly added to the reaction system, the reaction system was purged with nitrogen gas three times, and then the mixture was stirred at 25°C for 12 hours. The mixture was decompressed and spin-dried to obtain the hydrochloride salt of compound BB-13. MS-ESI m / z: 364.0 [M+H] + .

[0126] Example 1 [ka] Synthesis scheme: [ka] At room temperature and under the protection of nitrogen gas, compound BB-4 (0.3 g, 505.40 μmol) was dissolved in N,N-dimethylformamide (10 mL), BB-2 (123.44 mg, 505.40 μmol, hydrochloride), triethylamine (255.70 mg, 2.53 mmol, 351.72 μL), 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (288.25 mg, 758.10 μmol) were added, the reaction mixture was stirred at 20 ° C for 2 hours, and after the reaction was completed, water (50 mL) was added and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated saline (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was subjected to reduced pressure to remove the solvent. The resulting residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% hydrochloric acid) and lyophilized to obtain the target compound WX001. MS-ESI m / z: 820.2 [M+H] + . 1 H NMR(400 MHz, DMSO-d6)δ: 10.94(s, 1H), 10.61(s, 1H), 8.40(d, J=8.0 Hz, 1H), 8.29(d, J=1.6Hz, 1H), 8.08(m, 1H), 7.93-7.92(m, 2H), 7.57(d, J=8.8Hz, 1H), 7.49-7.43(m, 3H), 7.40(d, J=2.4Hz, 1H), 4.59(s, 2H), 4.15-4.11(m, 1H), 3.62-3.54(m, 6H), 2.90-2.51(m, 8H), 2.25-2.15(m, 2H), 1.52(s, 6H).

[0127] Example 2 [ka] Synthesis scheme: [ka] Compound BB-4 (100 mg, 168.47 μmol) and intermediate BB-1 (47.29 mg, 168.47 μmol) hydrochloride were added to N,N-dimethylformamide (2 mL), 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (96.08 mg, 252.70 μmol) and triethylamine (34.09 mg, 336.93 μmol, 46.90 μL) were slowly added to the reaction system, and the mixture was replaced with nitrogen gas three times and then stirred at 25° C. for 12 hours. The reaction solution was poured into 20 mL of water and 30 mL of ethyl acetate, the organic phase was separated and washed twice with water (20 mL x 2), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure, and the resulting residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% hydrochloric acid) to obtain compound WX002. MS-ESI m / z: 820.2 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ: 10.90(s, 1H), 10.47(br s, 1H), 8.40(d, J=8.3 Hz, 1H), 8.28(d, J=1.5 Hz, 1H), 8.13 - 7.97(m, 2H), 7.87(s, 1H), 7.54(d, J=8.5 Hz, 1H), 7.47 - 7.29(m, 3H), 7.26 - 7.13(m, 1H), 4.54(br s, 2H), 4.12(dd, J=4.8, 11.8 Hz, 1H), 3.67 - 3.45(m, 2H), 2.83 - 2.67(m, 2H), 2.63 - 2.43(m, 10H), 2.39 - 2.25(m, 1H), 2.19 - 2.03(m, 1H), 1.52(s, 6H).

[0128] Example 3 [ka] Synthesis scheme: [ka] Under the condition of room temperature and nitrogen gas protection, BB-3 hydrochloride (378 mg, 1.08 mmol) and BB-4 (767.86 mg, 1.29 mmol) were dissolved in N,N-dimethylformamide (5 mL) solvent, 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (614.82 mg, 1.62 mmol) and triethylamine (272.70 mg, 2.69 mmol) were added thereto, and the reaction mixture was stirred at 25 ° C for 3 hours. After the reaction was completed, water (50 mL) was added to the reaction solution, and it was extracted with ethyl acetate (100 mL × 2). The organic phases were combined, washed successively with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The resulting residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% hydrochloric acid) to obtain the target compound WX003. MS-ESI m / z: 870.1 [M+H] + . 1 H NMR(400 MHz, DMSO-d6)δ: 10.96(s, 1H), 10.73(s, 1H), 8.41-8.40(m, 2H), 8.39(d, J=1.6 Hz, 1H), 8.08(d, J=8.8 Hz, 1H), 8.07(dd, J=1.6, 8.4 Hz, 1H), 8.01(s, 1H), 7.78(s, 3H), 7.75(d, J=2.0 Hz, 1H), 7.46-7.37(m, 2H), 7.23(d, J=8.8 Hz, 1H), 4.68(dd, J=4.0, 11.2Hz, 1H), 4.58(s, 2H), 3.98(m, 1H), 3.47(s, 9H), 2.95 - 2.58(m, 3H), 2.49 - 2.21(m, 3H), 1.52(s, 6H).

[0129] Example 4 [ka] Synthesis scheme: [ka]

[0130] Step 1: Synthesis of WX004-1 Compound BB-5 (102.38 mg, 393.35 μmol) and BB-4-5 (150 mg, 262.23 μmol, 145.82 μL, hydrochloride salt) were added to dichloromethane (10 mL), triethylamine (53.07 mg, 524.46 μmol, 73.00 μL) was slowly added to the reaction system, the mixture was stirred at 25 ° C for 0.5 hours, sodium borohydride acetate (138.94 mg, 655.58 μmol) was slowly added to the reaction system, the mixture was purged with nitrogen gas three times, and then stirred at 25 ° C for 11.5 hours. The reaction system was slowly added to 50 mL of water, extracted three times with dichloromethane (50 mL × 3), and the organic phase was combined and spun dry under reduced pressure. The obtained residue was purified by column chromatography (eluent: dichloromethane / methanol = 1 / 0 to 5.7 / 1, volume ratio) to obtain compound WX004-1. MS-ESI m / z: 780.1 [M+H] + .

[0131] Step 2: Synthesis of WX004 Compound WX004-1 (280 mg, 309.14 μmol) and acrylamide (26.37 mg, 370.97 μmol, 25.60 μL) at 0°C were added to N,N-dimethylformamide (5 mL), potassium tert-butoxide (173.45 mg, 1.55 mmol) was slowly added to the reaction system through a hatch, the mixture was purged with nitrogen gas three times, and then stirred at 0°C for 1 hour. The reaction system was slowly added to a solution of saturated ammonium chloride, extracted twice with ethyl acetate (20 mL x 2), the organic phase was combined and washed twice with saturated saline (20 mL x 2), the organic phase was collected and dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The resulting residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the target compound WX004. MS-ESI m / z: 805.4 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ:10.89(s, 1H), 8.40(d, J=8.3 Hz, 1H), 8.28(d, J=1.0 Hz, 1H), 8.07(dd, J=1.4, 8.2 Hz, 1H), 7.85(d, J=6.8 Hz, 1H), 7.53(dd, J=4.0, 7.8 Hz, 1H), 7.49 - 7.32(m, 3H), 7.21(br d, J=8.8 Hz, 1H), 7.15(dd, J=5.5, 7.3 Hz, 1H), 4.53(br d, J=1.0 Hz, 2H), 4.12(dd, J=4.9, 11.9 Hz, 1H), 3.83 - 3.62(m, 5H), 3.27 - 3.06(m, 2H), 2.84 - 2.65(m, 3H), 2.57(br dd, J=4.1, 17.2 Hz, 4H), 2.49 - 2.42(m, 2H), 2.40 - 2.26(m, 1H), 2.19 - 2.01(m, 3H), 1.52(s, 6H).

[0132] Example 5 [ka] Synthesis scheme: [ka]

[0133] Step 1: Synthesis of intermediate WX005-1 At room temperature, BB-4-3 (1.00 g, 2.36 mmol) and bromoacetaldehyde diethyl acetal (512.01 mg, 2.60 mmol) were dissolved in N,N-dimethylformamide (10 mL), potassium carbonate (391.73 mg, 2.83 mmol) was added thereto, and the reaction mixture was stirred at 80 °C under nitrogen gas protection for 12 hours. After the reaction was completed, it was cooled to room temperature, water (50 mL) was added to the mixture, and it was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed successively with saturated saline (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 ~ 3 / 1, volume ratio) to obtain intermediate WX005-1. 1 H NMR (400MHz, CDCl3) δ: 8.01-7.94 (m, 2H), 7.84 (dd, J=2.0, 8.4 Hz, 1H), 7.16-7.10 (m, 1H), 7.09-7.00 (m, 2H), 4.88 (t, J=5.2 Hz, 1H), 4.13 (d, J=5.2 Hz, 2H), 3.86-3.76 (m, 2H), 3.72-3.62 (m, 2H), 1.59 (s, 6H), 1.27 (t, J=7.0 Hz, 6H).

[0134] Step 2: Synthesis of intermediate WX005-2 At room temperature, WX005-1 (500.00 mg, 926.71 μmol) was dissolved in ethanol (20 mL), and acetic acid (5.25 g, 87.42 mmol) and hydrochloric acid (1 M, 2.5 mL) were added thereto, and the reaction mixture was stirred at 80 ° C under the protection of nitrogen gas for 12 hours. After the reaction was completed, it was cooled to room temperature, concentrated under reduced pressure to remove the solvent (ethanol), water (30 mL) was added to the mixture, and extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed successively with saturated saline (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0 ~ 1 / 1, volume ratio) to obtain intermediate WX005-2. 1 H NMR (400MHz, CDCl3) δ: 9.92 (s, 1H), 8.02-7.92 (m, 2H), 7.84 (dd, J=2.0, 8.0 Hz, 1H), 7.19-7.10 (m, 1H), 7.10-7.01 (m, 2H), 4.74 (s, 2H), 1.60 (s, 6H).

[0135] Step 3: Synthesis of chemical WX005 Compound WX005-2 (40 mg, 85.94 μmol) was added to dichloromethane (10 mL) at 25° C., stirring was started, and then compound BB-6 (36.80 mg, 77.35 μmol) and sodium triacetoxyborohydride (54.65 mg, 257.83 μmol) were added. Stirring was continued for 12 hours under the protection of nitrogen gas. After the reaction was completed, water (50 mL) was added to the reaction solution, extracted with ethyl acetate (50 mL×2), the organic phase was combined, washed with half-saturated saline (50 mL×2), the organic phase was added, dried with anhydrous sodium sulfate, filtered, and spin-dried. The obtained residue was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the target compound WX005. ESI m / z: 846.2 [M+H] + . 1H NMR (400 MHz, DMSO-d6) δ:10.89 (s, 2H),9.77 (s, 1H),8.39 (d, J=8.4 Hz, 1H),8.27 (d, J=1.25 Hz, 1H),8.07 (d, J=8.4 Hz, 1 H),7.96 (d, J=1.2 Hz, 1H),7.88 (s, 1H),7.51 - 7.56 (m, 1H),7.44 - 7.50 (m, 1H),7.35 - 7.44 (m, 2H),7.21 -7.23 (m, 1H),4.61 (s, 2H),4.11 (dd, J=12.0, 4.8 Hz, 1H),3.5 -3.60 (m, 4H),3.50 -3.51 (m, 2H),2.93 - 3.02 (m, 2H),2.80 - 2.90 (m, 2H),2.70 - 2.79 (m, 1H),2.55 - 2.68 (m, 1H),2.22 - 2.35 (m, 1H),2.06 - 2.19 (m, 1H), 1.51 (s, 6H), 1.14 - 1.21 (m, 2H), 1.08-1.10 (m, 2H).

[0136] Example 6

change

change

[0137] ステップ1:Synthesis of chemical WX006-1 Compound BB-9 (71.00 mg, 499.50 μmol, 66.36 μL) and compound ethyl 2-formyl-1-cyclopropanecarboxylate (0.2 g, 416.25 μmol) were dissolved in a mixed solvent of dichloromethane (4 mL) and glacial acetic acid (0.1 mL), and sodium triacetoxyborohydride (132.33 mg, 624.38 μmol) was added at 20 ° C. and stirred at 20 ° C. for 15 hours. Water (2 mL) was added to the reaction solution, stirred for 10 minutes, saturated aqueous sodium bicarbonate solution (5 mL) was added, extracted with dichloromethane (5 mL × 4), the organic phase was washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound WX006-1 was obtained by separation and purification by preparative thin layer chromatography (developer: dichloromethane / methanol = 10 / 1).

[0138] Step 2: Synthesis of chemical WX006-2 Compound WX006-1 (0.11 g, 181.33 μmol) was dissolved in a mixed solvent of tetrahydrofuran (2 mL) and water (0.4 mL), lithium hydroxide monohydrate (38.05 mg, 906.65 μmol) was added, and the mixture was stirred at 20 ° C. for 15 hours. Ethyl acetate (5 mL) was added to the reaction solution, washed with 1N lithium hydroxide aqueous solution (2 mL × 5), the aqueous phase was adjusted to pH = 4-5 with 1N dilute hydrochloric acid, extracted with dichloromethane (5 mL × 3), and the organic phase was directly dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain compound WX006-2.

[0139] Step 3: Synthesis of chemical WX006 Compound WX006-2 (90 mg, 155.55 μmol) was dissolved in N,N-dimethylformamide (2 mL), 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (88.72 mg, 233.33 μmol) and N,N-diisopropylethylamine (100.52 mg, 777.77 μmol, 135.47 μL) were added, and the mixture was stirred for 10 minutes. Compound BB-8 hydrochloride (54.94 mg, 186.66 μmol) was then added, and the mixture was stirred at 20° C. for 60 hours. The reaction solution was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; neutral system) to obtain compound WX006. 1 H NMR (400 MHz, CD3OD) δ: 8.15-8.13 (m, 2H), 8.06-8.05 (m, 1H), 7.98 (t, J=10 Hz, 2H), 7.84 (s, 1H), 7.69 (d, J=9.2 Hz, 1H), 7.58 - 7.55 (m, 2H), 7.29 - 7.19 (m, 2H), 7.10- 7.08 (m, 1H), 4.65-4.61 (m, 1H), 4.33 (t, J=5.2 Hz, 2H), 3.07 (t, J=4.8 Hz, 2H), 2.92 - 2.84 (m, 1H), 2.77 - 2.70 (m, 2H), 2.61 - 2.58 (t, 1H), 2.55 (s, 3H) 2.46-2.42 (m, 2H), 1.94-1.91 (m, 1H), 1.67-1.65 (m, 1H), 1.52 (s, 6H), 1.35-1.31 (m, 1H), 0.95-0.90 (m, 1H).

[0140] Example 7 [ka] Synthesis scheme: [ka]

[0141] Step 1: Synthesis of chemical WX007-1 Compound WX007-2 (0.5 g, 3.47 mmol) was dissolved in dichloromethane (5 mL), the reaction solution was cooled to 0 °C, the reaction solution was added to Dess-Martin oxidant (2.94 g, 6.94 mmol, 2.15 mL) in batches, the temperature was slowly raised to 20 °C, and the mixture was stirred for 2 h. The reaction solution was poured into saturated aqueous sodium bicarbonate solution (10 mL) and 10% aqueous sodium thiosulfate solution (30 mL) at 0-10 °C, extracted with dichloromethane (10 mL × 3), and the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered to obtain a solution of compound WX007-3. The solution of compound WX007-3 and compound BB-9 (1.4 g, 2.91 mmol) were dissolved in dichloromethane (5 mL) and glacial acetic acid (0.1 mL), and sodium triacetoxyborohydride (1.24 g, 5.83 mmol) was added at 20 ° C. and stirred for 12 hours. Water (50 mL) was added to the reaction solution, and it was extracted with dichloromethane (30 mL × 3), and the organic phase was washed with saturated saline (20 mL × 3), dried with anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 ~ 0 / 1) to obtain compound WX007-1. 1 H NMR (400MHz, CDCl3) δ: 8.00-7.96 (m, 2H), 7.85 (dd, J = 1.6 Hz, 8.4 Hz, 1H), 7.14-7.02 (m, 3H), 4.21-4.18 (m, 2H), 4.13 (q, J = 7.2 Hz, 2H), 2.98-2.90 (m, 2H), 2.78 (s, 2H), 2.41 (s, 3H), 1.59 (s, 6H), 1.29-1.23 (m, 5H), 0.88-0.85 (m, 2H).

[0142] Step 2: Synthesis of compound WX007-4 Compound WX007-1 (0.53 g, 873.68 μmol) was dissolved in tetrahydrofuran (5 mL) and water (1 mL), lithium hydroxide monohydrate (183.30 mg, 4.37 mmol) was added, and the mixture was stirred at 20 ° C for 24 hours. The mixture was heated to 40 ° C and stirred for 24 hours. The reaction solution was adjusted to pH = 6-7 with 1N hydrochloric acid, most of the tetrahydrofuran was spun off, methyl tert-butyl ether (30 mL) and 10% potassium carbonate aqueous solution (20 mL × 3) were added, separated, the aqueous phase was adjusted to pH = 5-6 with 1N hydrochloric acid, extracted with dichloromethane (50 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure to obtain compound WX007-4.

[0143] Step 3: Synthesis of chemical WX007 Compound WX007-4 (50 mg, 86.42 μmol) and N,N-diisopropylethylamine (44.68 mg, 345.68 μmol, 60.21 μL) were dissolved in N,N-dimethylformamide (2 mL), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (39.43 mg, 103.70 μmol) was added at 20 ° C. and stirred for 5 minutes, and compound BB-8 hydrochloride (34.30 mg, 103.70 μmol) was added and stirred at 20 ° C. for 12 hours. The reaction solution was concentrated under reduced pressure, and the solvent was removed to obtain a crude product, which was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain compound WX007. 1H NMR (400 MHz, CD3OD) δ: 8.17-8.15 (m, 3H), 7.98 (d, J=8.4 Hz, 1H), 7.87-7.84 (m, 2H), 7.74 (d, J=9.6 Hz, 1H), 7.62 (t, J=7.6 Hz, 1H), 7.45 (d, J=7.2 Hz, 1H), 7.28-7.25 (m, 2H), 7.12 (d, J=8.8 Hz, 1H), 4.65 (dd, J=5.6 Hz, 11.2 Hz, 1H), 4.52 (t, J=4.4 Hz, 2H), 3.90 (dd, J=4.0 Hz, 13.2 Hz, 1H), 3.83-3.79 (m, 1H), 3.65-3.61 (m, 1H), 3.32-3.29 (m, 1H), 3.08 (s, 3H), 2.94-2.85 (m, 1H), 2.77-2.72 (m, 1H), 2.53-2.43 (m, 2H), 1.92-1.84 (m, 2H), 1.53 (s, 6H), 1.48-1.45 (m, 1H), 1.39-1.35 (m, 1H).

[0144] Example 8

change

change

[0145] ステップ1:Synthesis of chemical WX008-2 Compound WX008-1 (100 g, 460.70 mmol) and acetyl chloride (54.25 g, 691.05 mmol, 49.31 mL) were dissolved in dichloromethane (1000 mL), purged and protected with nitrogen gas, and aluminum trichloride (92.15 g, 691.05 mmol, 37.76 mL) was added in batches at 20 °C, and the reaction solution was stirred for 2 hours. The reaction solution was poured into 6N glacial hydrochloric acid (400 mL), extracted with dichloromethane (700 mL × 3), the organic phase was washed with saturated saline (700 mL × 3), dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain a crude product, which was slurried in methanol (500 mL), stirred for 15 minutes, filtered, and the cake was rinsed with methanol (100 mL × 2), and the cake was collected to obtain compound WX008-2.

[0146] Step 2: Synthesis of chemical WX008-3 WX008-2 (20 g, 77.19 mmol) was dissolved in dichloromethane (200 mL), cooled to -70 ° C., boron tribromide (17.40 g, 69.47 mmol, 6.69 mL) was added dropwise, and the mixture was slowly warmed to 20 ° C. and stirred for 1 hour. The reaction solution was poured into 4N hydrochloric acid (100 mL), extracted with ethyl acetate (100 mL × 3), the organic phase was washed with saturated saline (100 mL × 3), dried over anhydrous sodium sulfate, filtered, spin-dried, and the resulting residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 7 / 1) to obtain compound WX008-3.

[0147] Step 3: Synthesis of chemical WX008-4 Compound WX008-3 (13.84 g, 56.47 mmol) was dissolved in chloroform (70 mL) and ethyl acetate (70 mL), copper bromide (25.23 g, 112.95 mmol, 5.29 mL) was added, and the mixture was heated to 90° C. and stirred for 16 hours. The reaction solution was cooled to room temperature, filtered, and the cake was rinsed with dichloromethane (110 mL) to obtain a dichloromethane solution of compound WX008-4.

[0148] Step 4: Synthesis of chemical WX008-5 At 0° C., triethylamine (11.43 g, 112.97 mmol, 15.72 mL) was slowly added dropwise to the dichloromethane solution of compound WX008-4, and after the completion of the addition, the temperature was raised to 20° C. and stirred for 2 hours. The organic phase was washed with saturated aqueous ammonium chloride solution (100 mL×3), dried over anhydrous sodium sulfate, and filtered to obtain a dichloromethane solution of compound WX008-5.

[0149] Step 5: Synthesis of chemical WX008-6 Toluene (150mL) and ethoxycarbonylmethylenetriphenylphosphorane (23.62g, 67.79mmol) were added to the dichloromethane solution of WX008-5, and the mixture was heated to 130°C, and the low boiling point solvent was separated using a water separator, and the mixture was stirred for 12 hours. The mixture was cooled to room temperature and directly concentrated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate=10 / 1) to obtain compound WX008-6. 1H NMR (400 MHz, CDCl3) δ: 7.70 (s, 1H), 7.60 (s, 1H), 7.05 (s, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.95 (s, 3H), 3.67 (s, 2H), 1.28 (t, J = 7.2Hz, 3H).

[0150] Step 6: Synthesis of chemical WX008-7 Compound WX008-6 (4 g, 12.77 mmol) was dissolved in dichloromethane (40 mL), cooled to -70 ° C, boron tribromide (3.36 g, 13.41 mmol, 1.29 mL) was added dropwise, and the mixture was stirred for 0.5 hours, slowly warmed to 0 ° C, and stirred for 1 hour. The mixture was cooled to -70 ° C, boron tribromide (3.36 g) was added, and the mixture was slowly warmed to 0 ° C, and stirred for 1 hour. The reaction solution was poured into 1N hydrochloric acid (50 mL), extracted with dichloromethane (50 mL × 3), and the organic phase was washed with saturated saline (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain compound WX008-7.

[0151] Step 7: Synthesis of chemical WX008-8 Compound WX008-7 (1.8 g, 6.02 mmol) and potassium carbonate (1.83 g, 13.24 mmol) were placed in N,N-dimethylformamide (10 mL), 2-bromo-1,1-dimethoxyethane (1.22 g, 7.22 mmol, 847.58 μL) was added, and the mixture was heated to 100 ° C. and stirred for 12 hours. The reaction solution was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 3), and the organic phase was washed with saturated saline (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain compound WX008-8.

[0152] Step 8: Synthesis of chemical WX008-9 Compound WX008-8 (1.84 g, 4.75 mmol) was placed in toluene (20 mL), polyphosphoric acid (1.84 g, 8.74 mmol) was added, and the mixture was heated to 100° C. and stirred for 12 hours. The reaction solution was cooled to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL×3). The organic phase was washed with saturated aqueous sodium bicarbonate solution (30 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate=10 / 1) to obtain compound WX008-9. 1 H NMR (400MHz, CDCl3) δ: 7.81 (d, J = 2.4 Hz, 1H), 7.71 (m, 1H), 7.66 (s, 1H), 7.13 (d, J = 2.0 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.85 (d, J = 0.8 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H).

[0153] Step 9: Synthesis of Chemical WX008-10 Compound WX008-9 (700 mg, 2.17 mmol), 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (128.78 mg, 303.28 μmol), tert-butyl carbamate (304.53 mg, 2.60 mmol), potassium phosphate (1.84 g, 8.67 mmol) and tris(dibenzylideneacetone)dipalladium (138.86 mg, 151.64 μmol) were placed in toluene (10 mL) and water (2 mL), substituted and protected with nitrogen gas, heated to 100 °C and stirred for 6 hours. The reaction solution was cooled to room temperature, water (20 mL) was added, extracted with ethyl acetate (20 mL × 3), and the organic phase was washed with saturated saline (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was added with n-heptane (10 mL) and stirred for 15 min, filtered, the cake was rinsed with n-heptane (3 mL×3), and the cake was collected to give compound WX008-10.

[0154] Step 10: Synthesis of Chemical WX008-11 Compound WX008-10 (760 mg, 2.11 mmol) and acrylamide (165.35 mg, 2.33 mmol, 160.53 μL) were dissolved in N,N-dimethylformamide (20 mL), potassium tert-butoxide (498.34 mg, 4.44 mmol) was added at 20 ° C, and the mixture was stirred at 20 ° C for 1 hour. The reaction solution was poured into 1N hydrochloric acid (20 mL) at 0-10 ° C, extracted with ethyl acetate (20 mL × 3), and the organic phase was washed with saturated saline (20 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain compound WX008-11.

[0155] Step 11: Synthesis of the hydrochloride salt of compound WX008-12 Compound WX008-11 (240 mg, 624.38 μmol) was placed in ethyl acetate (1 mL), hydrogen chloride·ethyl acetate (4 M, 10 mL) was added, and the mixture was stirred at 20° C. for 3 hours. The reaction solution was directly concentrated under reduced pressure to obtain the hydrochloride salt of compound WX008-12. 1H NMR (400 MHz, DMSO-d6) δ: 10.94 (s, 1H), 8.16 (d, J = 2.0 Hz, 1H), 7.87 (s, 1H), 7.26 (s, 1H), 7.09 (d, J = 2.0 Hz, 1H), 4.29 (dd, J = 4.8 Hz, 12.0 Hz, 1H), 2.86-2.77 (m, 1H), 2.68-2.58 (m, 1H), 2.34-2.22 (m, 1H), 2.19-2.14 (m, 1H).

[0156] Step 12: Synthesis of Chemical WX008 Compound BB-4 (125.29 mg, 211.07 μmol) and N,N-diisopropylethylamine (90.93 mg, 703.57 μmol) were dissolved in N,N-dimethylformamide (2 mL), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (86.94 mg, 228.66 μmol) was added at 20°C and stirred for 5 minutes. Compound WX008-12 hydrochloride (50 mg, 175.89 μmol) was added at 20°C and stirred for 12 hours. The reaction solution was directly concentrated under reduced pressure. The crude product was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain compound WX008. 1H NMR (400 MHz, CD3OD) δ: 8.19 (s, 1H), 8.17-8.15 (m, 2H), 7.98 (dd, J = 1.6 Hz, 8.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.81 (s, 1H), 7.40-7.35 (m, 1H), 7.32 (dd, J = 2.4 Hz, 11.6 Hz, 1H), 7.25-7.22 (m, 1H), 7.02 (d, J = 2.0 Hz, 1H), 4.60-4.58 (m, 2H), 4.29 (dd, J = 5.2 Hz, 11.6 Hz, 1H), 3.92 (s, 2H), 3.77-3.69 (m, 6H), 3.42 (m, 4H), 2.92-2.83 (m, 1H), 2.79-2.73 (m, 1H), 2.44-2.30 (m, 2H), 1.57 (s, 6H).

[0157] Example 9

change

change

[0158] Example 10 [ka] Synthesis scheme: [ka]

[0159] Step 1: Synthesis of chemical WX010-1 Compound BB-3-4 (2 g, 6.00 mmol) was added to a solvent of dioxane (20 mL) at room temperature, stirring was started, and compound bis(pinacolato)diboron (2.29 g, 9.00 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (439.23 mg, 600.28 μmol) and potassium acetate (1.18 g, 12.01 mmol) were added, and the reaction solution was heated to 100 ° C. and stirred for 12 hours under the protection of nitrogen gas. After the reaction was completed, the reaction solution was cooled to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with half-saturated saline (30 mL x 2), added to the organic phase, dried over anhydrous sodium sulfate, filtered, and spin-dried. The resulting crude product was separated and purified by column chromatography (eluent, petroleum ether: ethyl acetate = 1 / 0 to 4 / 1) to obtain compound WX010-1. MS-ESI m / z: 380.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ: 8.47 (s, 1H), 8.19 (d, J=8.5 Hz, 1H), 7.94 (d, J=8.3 Hz, 1H), 7.83 - 7.75 (m, 2H), 7.65 (d, J=9.0 Hz, 1H), 4.23 (q, J=7.1 Hz, 2H), 4.09 - 4.09 (m, 1H), 4.08 (s, 1H), 1.41 (s, 12H), 1.30 - 1.25 (m, 3H).

[0160] Step 2: Synthesis of compound WX010-2 Compound WX010-1 (2.3 g, 6.05 mmol) was added to a mixed solvent of tetrahydrofuran (40 mL) and water (20 mL) at room temperature, stirring was started, compound sodium hydrogen carbonate (1.02 g, 12.10 mmol, 470.52 μL) was added, the reaction solution was cooled to 0 ° C, hydrogen peroxide (5.49 g, 48.39 mmol, 4.65 mL, 30% concentration) was slowly added dropwise to the reaction solution, and stirring was continued for 2 hours under the protection of nitrogen gas. Saturated aqueous sodium sulfite solution (50 mL) was slowly added dropwise to the reaction solution in an ice bath, and stirring was continued for 10 minutes after the completion of the dropwise addition. Extraction was performed by adding ethyl acetate (100 mL × 2). Anhydrous sodium sulfate was added to the organic phase to dry it, then it was filtered and spin-dried. The crude product was separated and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 8 / 1 ~ 4 / 1) to obtain compound WX010-2. 1 H NMR (400MHz, CDCl3) δ:8.13 (d, J=8.9 Hz, 1H), 7.74 (s, 1H), 7.64 - 7.51 (m, 2H), 7.29 (d, J=2.6 Hz, 1H), 7.18 (dd, J=2.6, 8.9 Hz, 1H), 4.23 (q, J=7.1 Hz, 2H), 4.05 (d, J=0.9 Hz, 2H), 1.31 - 1.22 (m, 3H).

[0161] Step 3: Synthesis of compound WX010-3 Compound WX010-2 (400 mg, 1.33 mmol) and 1,5-dibromopentane (1.53 g, 6.64 mmol, 897.79 μL) were added to N,N-dimethylformamide (10 mL), stirring was started, potassium carbonate (550.41 mg, 3.98 mmol) and sodium iodide (198.99 mg, 1.33 mmol) were slowly added to the reaction system, the mixture was purged with nitrogen gas three times, and then stirred at 80 ° C for 10 hours. The reaction solution was cooled to 25 ° C, ethyl acetate (30 mL) and water (30 mL) were added thereto, the organic phase was separated, and washed twice with saturated saline (30 mL × 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and spun dry under reduced pressure. The crude product was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 50 / 1 to 10 / 1) to obtain compound WX010-3. MS-ESI m / z: 418.9 [M+H] + . 1 H NMR (400MHz,CDCl3) δ: 8.06 (d, J=9.0 Hz, 1H), 7.66 (s, 1H), 7.53 (s, 2H), 7.25 - 7.10 (m, 3H), 4.17 - 4.08 (m, 3H), 4.03 (t, J=6.3 Hz, 2H), 3.96 (s, 2H), 3.39 (t, J=6.8 Hz, 2H), 1.97 - 1.86 (m, 2H), 1.85 - 1.77 (m, 2H), 1.69 - 1.57 (m, 3H), 1.18 (t, J=7.2 Hz, 3H).

[0162] Step 4: Synthesis of compound WX010-4 Compound BB-10 (200 mg, 422.37 μmol) and WX010-3 (177.11 mg, 422.37 μmol, 72.61 μL) were added to N,N-dimethylformamide (5 mL), stirring was started, potassium carbonate (175.12 mg, 1.27 mmol) and potassium iodide (70.12 mg, 422.37 μmol) were slowly added to the reaction system, the reaction solution was replaced with nitrogen gas three times, and then stirred at 80 ° C for 12 hours. The reaction solution was cooled to room temperature, diluted with ethyl acetate (30 mL), the organic phase was washed twice with water (20 mL × 2), the organic phase was collected and dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure. The obtained crude product was separated and purified by column chromatography (eluent: dichloromethane / methanol = 50 / 1 ~ 10 / 1) to obtain compound WX010-4. MS-ESI m / z: 812.3 [M+H] + .

[0163] Step 5: Synthesis of Chemical WX010 Compound WX010-4 (300 mg, 369.50 μmol) and acrylamide (26.26 mg, 369.50 μmol, 25.50 μL) were added to N,N-dimethylformamide (10 mL) at 0°C, potassium tert-butoxide (82.92 mg, 739.00 μmol) was slowly added to the reaction system in batches, the mixture was replaced with nitrogen gas three times, and then stirred at 0°C for 1 hour. The reaction system was slowly added to saturated ammonium chloride (50 mL), extracted twice with ethyl acetate (50 mL x 2), the organic phase was combined and washed three times with saturated saline (30 mL x 3), the organic phase was dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure. The crude product was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain compound WX010. MS-ESI m / z: 837.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ:11.23 (br s, 1H), 10.95 (s, 1H), 8.39 (d, J=8.3 Hz, 1H), 8.30 (d, J=1.3 Hz, 1H), 8.15 - 8.04 (m, 2H), 7.98 (d, J=6.8 Hz, 1H), 7.82 - 7.68 (m, 2H), 7.53 (d, J=2.3 Hz, 1H), 7.34 - 7.20 (m, 3H), 7.14 (br d, J=9.0 Hz, 2H), 4.65 (br dd, J=4.1, 11.9 Hz, 1H), 4.18 - 4.09 (m, 2H), 4.03 (s, 1H), 3.93 (br s, 2H), 3.60 (br d, J=11.3 Hz, 2H), 3.38 - 3.23 (m, 2H), 3.22 - 3.04 (m, 4H), 2.98 - 2.79 (m, 1H), 2.71 - 2.53 (m, 1H), 2.41 (br dd, J=3.9, 12.7 Hz, 1H), 2.31 - 2.17 (m, 1H), 1.95 - 1.76 (m, 4H), 1.64 - 1.43 (m, 8H).

[0164] Example 11

change

change

[0165] ステップ1:Synthesis of chemical WX011-1 Compound BB-4-3 (1 g, 2.36 mmol) was dissolved in N,N-dimethylformamide (30 mL), potassium carbonate (652.86 mg, 4.72 mmol) and 2,2'-dibromodiethyl ether (2.74 g, 11.81 mmol, 1.48 mL) were added, and the mixture was heated to 80 ° C. and stirred for 30 hours. Water (150 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3), and the organic phase was washed with saturated saline (50 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound WX011-1 was obtained by purification by column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1).

[0166] Step 2: Synthesis of compound WX011-2 1-Aminocyclopropane ethyl carboxylate hydrochloride (346.01 mg, 2.09 mmol) and potassium carbonate (577.48 mg, 4.18 mmol) were dissolved in N,N-dimethylformamide (10 mL), compound WX011-1 (0.6 g, 1.04 mmol) was added, and the mixture was heated to 75° C. and stirred for 15 hours. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (15 mL×2), and the organic phase was washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (eluent: petroleum ether / ethyl acetate=3 / 1) to obtain compound WX011-2.

[0167] Step 3: Synthesis of compound WX011-3 Compound WX011-2 (0.2 g, 321.22 μmol) was dissolved in a mixed solvent of tetrahydrofuran (4 mL) and water (1 mL), and lithium hydroxide monohydrate (67.40 mg, 1.61 mmol) was added at 20° C. and stirred for 30 hours. Water (5 mL) was added to the reaction solution, and the pH was adjusted to 5 with 1N dilute hydrochloric acid, extracted with ethyl acetate (10 mL×4), and the organic phase was washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain compound WX011-3.

[0168] Step 4: Synthesis of chemical WX011 Compound WX011-3 (80 mg, 134.55 μmol) was dissolved in N,N-dimethylformamide (1 mL), 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (76.74 mg, 201.82 μmol) and N,N-diisopropylethylamine (69.56 mg, 538.20 μmol, 93.74 μL) were added, and the mixture was stirred for 10 minutes. Compound BB-1 hydrochloride (49.10 mg, 174.91 μmol) was added, and the mixture was stirred at 20° C. for 15 hours. The reaction solution was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain compound WX011. 1 H NMR (400 MHz, CD3OD) δ: 8.16-8.14 (m, 2H), 7.95 (dd, J=1.6 Hz, 8.4 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.71 (s, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.30-7.22 (m, 3H), 7.16-7.14(m, 1H), 4.35 (t, J = 4.0 Hz, 2H), 4.10 (dd, J=4.2 Hz, 11.6 Hz, 1H), 3.99-3.97 (m, 2H), 3.89 (t, J = 2.8 Hz, 2H), 3.47 (s, 2H), 2.83-2.66 (m, 2H), 2.42-2.32 (m, 1H), 2.29-2.22 (m, 1H), 1.81-1.78 (m, 2H), 1.65-1.63 (m, 2H), 1.54 (s, 9H).

[0169] Example 12 [ka] Synthesis scheme: [ka]

[0170] Step 1: Synthesis of chemical WX012-1 Compound BB-10 and ethyl 5-bromovalerate (662.33 mg, 3.17 mmol, 505.59 μL) were added to N,N-dimethylformamide (5 mL), stirring was started, potassium carbonate (262.69 mg, 1.90 mmol) and sodium iodide (94.97 mg, 633.56 μmol) were slowly added to the reaction system, the reaction solution was replaced with nitrogen gas three times, and then stirred at 80 ° C for 12 hours. After the reaction was completed, it was cooled to 25 ° C, diluted with ethyl acetate (20 mL), the organic phase was washed twice with water (20 mL × 2) and once with saturated saline (20 mL), the organic phase was collected and dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure. The crude product was separated and purified by column chromatography (eluent: dichloromethane / methanol = 50 / 1 ~ 10 / 1) to obtain compound WX012-1. MS-ESI m / z:602.1[M+H] + .

[0171] Step 2: Synthesis of compound WX012-2 Compound WX012-1 (170 mg, 282.54 μmol) was added to anhydrous ethanol (2.5 mL) and water (0.5 mL), stirring was started, lithium hydroxide monohydrate (29.64 mg, 706.35 μmol) was slowly added to the reaction system, the reaction solution was replaced with nitrogen gas three times, and then stirred at 25 ° C for 12 hours. After the reaction was completed, water (10 mL) was added to the reaction solution, most of the organic solvent was spun off under reduced pressure, the aqueous phase was adjusted to pH = 3 with 2N hydrochloric acid, and the aqueous phase was directly freeze-dried. Compound WX012-2 was obtained. MS-ESI m / z: 574.0 [M + H] + .

[0172] Step 3: Synthesis of the hydrochloride salt of compound WX012 Compound BB-3 hydrochloride (54.30 mg, 139.46 μmol) was added to N,N-dimethylformamide (5 mL), 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (165.71 mg, 435.82 μmol) and triethylamine (52.92 mg, 522.99 μmol, 72.79 μL) were slowly added to the reaction system, and the mixture was replaced with nitrogen gas three times, and then stirred at 25 ° C. for 3 hours. The reaction system was diluted with ethyl acetate (30 mL), the organic phase was washed twice with water (20 mL × 2), the organic phase was collected, dried over anhydrous sodium sulfate, filtered, spin-dried under reduced pressure, and the crude product was separated by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the hydrochloride of compound WX012. MS-ESI m / z: 850.4[M+H] + . 1 H NMR (400MHz, DMSO-d6) δ:10.95 (s, 1H), 10.54 (br d, J=4.5 Hz, 1H), 10.29 (s, 1H), 8.48 - 8.35 (m, 2H), 8.29 (d, J=1.3 Hz, 1H), 8.18 - 8.04 (m, 2H), 7.99 (s, 1H), 7.79 - 7.69 (m, 3H), 7.28 - 7.21 (m, 2H), 7.14 (d, J=9.0 Hz, 2H), 4.65 (br dd, J=4.4, 12.2 Hz, 1H), 3.94 (br d, J=11.3 Hz, 2H), 3.62 (br d, J=10.8 Hz, 2H), 3.28 - 3.07 (m, 6H), 2.95 - 2.80 (m, 1H), 2.69 - 2.59 (m, 1H), 2.49 - 2.36 (m, 3H), 2.33 - 2.22 (m, 1H), 1.92 - 1.77 (m, 2H), 1.76 - 1.65 (m, 2H), 1.49 (s, 6H).

[0173] Example 13 [ka] Synthesis scheme: [ka]

[0174] Step 1: Synthesis of chemical WX013-1 Compound BB-10 (0.15 g, 284.79 μmol) and ethyl bromopropionate (103.11 mg, 569.57 μmol, 72.61 μL) were added to acetonitrile (5 mL), stirring was started, potassium carbonate (78.72 mg, 569.57 μmol) and potassium iodide (47.28 mg, 284.79 μmol) were slowly added to the reaction system, the reaction solution was replaced with nitrogen gas three times, and then stirred at 80 ° C for 2 hours. The reaction solution was cooled to room temperature, ethyl acetate (50 mL) and water (50 mL) were added, and the organic phase was separated and washed twice with saturated saline (30 mL × 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure. The crude product was purified by column chromatography (eluent: dichloromethane / methanol = 50 / 1 to 10 / 1, volume ratio) to obtain compound WX013-1. MS-ESI m / z: 574.0 [M+H] + .

[0175] Step 2: Synthesis of compound WX013-2 Compound WX013-1 (0.2 g, 348.66 μmol) was added to anhydrous ethanol (4 mL) and water (1 mL), stirring was started, lithium hydroxide monohydrate (43.89 mg, 1.05 mmol) was slowly added to the reaction system, the reaction solution was purged with nitrogen gas three times, and then stirred at 25 ° C for 12 hours. The reaction system was decompressed to spin off most of the ethanol, and 20 mL of water was added. The aqueous phase was adjusted to pH = 3-4 with 2N hydrochloric acid, and the aqueous phase was directly freeze-dried. Compound WX013-2 was obtained. MS-ESI m / z: 546.0 [M + H] + .

[0176] Step 3: Synthesis of the hydrochloride salt of compound WX013 Compound WX013-2 (60 mg, 109.98 μmol) and hydrochloride of BB-3 were added to N,N-dimethylformamide (3 mL), and 2-(7-azabenzotriazolyl)-N,N,N',N'-tetramethylurea hexafluorophosphate (83.63 mg, 219.95 μmol) and N,N-diisopropylethylamine (42.64 mg, 329.93 μmol, 57.47 μL) were slowly added to the reaction system. The mixture was purged with nitrogen gas three times and then stirred at 20° C. for 12 hours. After the reaction was completed, the reaction solution was poured into a mixed solvent of water and ethyl acetate (10 mL:10 mL), the organic phase was separated and washed three times with water (10 mL x 3), the organic phase was collected and dried over anhydrous sodium sulfate, filtered, and spin-dried under reduced pressure, and the crude product was purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the hydrochloride salt of compound WX013. MS-ESI m / z: 822.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 10.95 (s, 1H), 10.54 (br s, 1H), 10.46 (br s, 1H), 8.47 - 8.35 (m, 2H), 8.29 (br s, 1H), 8.16 (br s, 1H), 8.08 (br d, J=8.5 Hz, 1H), 8.00 (s, 1H), 7.80 - 7.67 (m, 3H), 7.34 - 7.20 (m, 2H), 7.16 (br d, J=8.8 Hz, 2H), 4.68 (br s, 1H), 3.98 (m, 2H), 3.64 (m, 2H), 3.55 (m, 4H), 3.23 (m, 2H), 3.05 (br s, 2H), 2.86 (m, 1H), 2.67 (m, 1H), 2.63 - 2.62 (m, 1H), 2.41 - 2.33 (m, 1H), 1.49 (br s, 6H).

[0177] Example 14 [ka] Synthesis scheme: [ka]

[0178] Synthesis of the hydrochloride salt of compound WX014 Compound BB-11 (400 mg, 854.80 μmol) and the hydrochloride salt of compound BB-12 (403.83 mg, 1.11 mmol) were dissolved in dichloromethane (30 mL), sodium boron acetate (543.50 mg, 2.56 mmol) was added, and the reaction mixture was stirred at room temperature for 12 hours under the protection of nitrogen gas. After the reaction was completed, dichloromethane (100 mL) and water (100 mL) were added to dilute the reaction solution, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, the organic phase was concentrated under reduced pressure, and the obtained crude product was purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the hydrochloride salt of compound WX014. MS-ESI m / z: 815.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ: 10.97 (s, 1H), 10.83 (br s, 1H), 8.63 (d, J=8.0 Hz, 1H), 8.05 (br d, J=8.5 Hz, 1H), 7.96 (s, 1H), 7.91 - 7.84 (m, 2H), 7.73 (s, 2H), 7.54 - 7.43 (m, 3H), 7.41 - 7.38 (m, 1H), 7.16 - 7.11 (m, 1H), 4.63 (br dd, J=4.0, 12.0 Hz, 1H), 4.58 - 4.46 (m, 3H), 3.98 - 3.81 (m, 3H), 3.66 (br d, J=11.0 Hz, 2H), 3.43 (br t, J=12.2 Hz, 2H), 3.28 - 3.05 (m, 6H), 2.96 - 2.83 (m, 1H), 2.76 - 2.58 (m, 2H), 2.56 - 2.53 (m, 1H), 2.46 - 2.37 (m, 1H), 2.31 - 2.21 (m, 2H), 2.11 (br d, J=9.0 Hz, 2H), 2.02 (br d, J=12.0 Hz, 2H), 1.90 (br d, J=10.5 Hz, 2H), 1.72 - 1.58 (m, 2H), 1.58 - 1.45 (m, 2H).

[0179] Example 15

change

change

[0180] Synthesis of compound WX015 acid chloride Compound BB-11 (400 mg, 854.80 μmol) and the hydrochloride salt of compound BB-13 (403.83 mg, 1.11 mmol) were dissolved in dichloromethane (30 mL), sodium boron acetate (181.17 mg, 854.80 μmol) was added, and the reaction mixture was stirred at room temperature for 12 hours under the protection of nitrogen gas. After the reaction was completed, dichloromethane (100 mL) and water (100 mL) were added to dilute the reaction solution, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure, and the obtained crude product was purified by preparative HPLC (mobile phase: acetonitrile / water; acidic system: 0.05% HCl) to obtain the hydrochloride salt of compound WX015. MS-ESI m / z: 815.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 10.96 (s, 1H), 10.82 (br s, 1H), 8.63 (d, J=8.3 Hz, 1H), 8.17 (d, J=9.3 Hz, 1H), 8.03 (s, 1H), 7.96 (br d, J=5.8 Hz, 1H), 7.86 (dt, J=9.4, 15.6 Hz, 3H), 7.60 - 7.51 (m, 2H), 7.39 (d, J=2.5 Hz, 1H), 7.27 - 7.22 (m, 1H), 7.14 (dd, J=2.3, 8.8 Hz, 1H), 4.68 (br dd, J=3.9, 11.9 Hz, 1H), 4.58 - 4.47 (m, 3H), 3.92 - 3.81 (m, 1H), 3.69 (br s, 3H), 3.50 - 3.38 (m, 3H), 3.23 - 3.06 (m, 4H), 2.98 - 2.81 (m, 1H), 2.70 - 2.58 (m, 1H), 2.45 - 2.20 (m, 4H), 2.16 - 1.99 (m, 5H), 1.91 (br d, J=10.3 Hz, 2H), 1.71 - 1.58 (m, 2H), 1.57 - 1.42 (m, 2H), 1.40 - 1.27 (m, 2H).

[0181] Example 16 and Example 17 [ka] Synthesis scheme: [ka]

[0182] Synthesis of Compound 16 and Compound 17 Compound BB-11 (7 g, 14.96 mmol) and the hydrochloride salt of compound BB-13 (7.18 g, 17.95 mmol) were dissolved in dichloromethane (500 mL) and stirred at room temperature for 12 hours. Sodium boroacetate (4.76 g, 22.44 mmol) was added, and the reaction mixture was stirred at room temperature for 12 hours under the protection of nitrogen gas. After the reaction was completed, water (200 mL) was added to dilute the reaction solution, the organic phase was separated, washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, the organic phase was concentrated under reduced pressure, and the resulting crude product was separated by column chromatography (eluent: dichloromethane: methanol = 10 / 1) to obtain compound WX015, and compound WX015 was separated by chiral HPLC (column: DAICEL CHIRALPAK IE (250 mm × 30 mm, 10 μm); mobile phase: A (IPA), B (ACN), B%: 50% ~ 100%; flow rate: 80 mL / min) to obtain compounds WX016 and WX017.

[0183] Analytical method: Column: Chiralpak IA 100×4.6 mm, 3 μm; Mobile phase: A: n-hexane (0.1% diethylamine); B: isopropanol:acetonitrile=2:1, A:B=40:60; Column temperature: 35° C.; Wavelength: 220 nm. WX016: Retention time: 4.679min, ee%:98.77%;MS-ESI m / z: 815.4 [M+H] + . 11H NMR (400 MHz, DMSO-d6) δ: 10.97 (s, 1H), 8.60 (d, J = 8.3 Hz, 1H), 8.16 (d, J = 9.3 Hz, 1H), 7.99 (s, 1H), 7.91 - 7.74 (m, 4H), 7.51 (t, J = 7.9 Hz, 1H), 7.41 - 7.31 (m, 2H), 7.21 - 7.10 (m, 2H), 4.66 (br dd, J = 4.1, 11.7 Hz, 1H), 4.58 - 4.45 (m, 3H), 3.94 - 3.79 (m, 1H), 3.22 3.00 (m, 7H), 2.89 (ddd, J = 5.3, 12.2, 17.4 Hz, 2H), 2.69 - 2.56 (m, 2H), 2.47 - 2.33 (m, 2H), 2.29 (br d, J = 7.0 Hz, 3H), 2.11 (br d, J = 9.3 Hz, 2H), 2.00 - 1.81 (m, 5H), 1.72 - 1.58 (m, 2H), 1.58 - 1.44 (m, 2H), 1.26 - 1.09 (m, 2H). WX017: Retention time: 5.797 min, ee%: 99.86%; MS-ESI m / z: 815.4 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ = 11.00 (br s, 1H), 8.60 (br d, J=8.3 Hz, 1H), 8.22 - 8.13 (m, 1H), 8.04 - 7.95 (m, 1H), 7.94 - 7.71 (m, 4H), 7.57 - 7.47 (m, 1H), 7.41 - 7.31 (m, 2H), 7.16 (br dd, J=8.0, 19.1 Hz, 2H), 4.66 (br d, J=7.3 Hz, 1H), 4.58 - 4.40 (m, 3H), 3.87 (br d, J=7.8 Hz, 1H), 3.28 - 2.97 (m, 7H), 2.88 (br t, J=12.3 Hz, 2H), 2.69 - 2.56 (m, 2H), 2.49 - 2.35 (m, 2H), 2.28 (br d, J=6.0 Hz, 3H), 2.17 - 2.00 (m, 2H), 2.00 - 1.79 (m, 5H), 1.71 - 1.58 (m, 2H), 1.51 (q, J=10.6 Hz, 2H), 1.26 - 1.01 (m, 2H).

[0184] Biological Data Test Example 1: In vitro study of AR protein levels and downstream effector prostate-specific antigen (PSA) protein regulation in human prostate cancer LNCaP cells Experimental Objective: To study the regulation of AR protein level and downstream effector prostate specific antigen (PSA) protein by different concentrations of compounds in human prostate cancer LNCaP cells using WB (Western Blot) method.

[0185] Experimental scheme: 1) Thaw and passage LNCaP cells at least twice; 2) LNCaP cells were plated in a 6-well plate with 3 x 10 cells in each well. 5 Seed with cells, allow to attach overnight and then treat with a given concentration of test compound; 3) After 24 hours of treatment, the supernatant of the cultured cell sample was discarded and washed twice with DPBS (Dulbecco's phosphate-buffered saline), and then the cells were lysed in a predetermined amount of 2% SDS lysate preheated at 100°C, collected, and denatured at 100°C for 15 minutes; 4) After denaturing and cooling the above lysate, perform a protein quantification test (Pierce BCA Protein Test Kit, Thermo), then add 5x loading buffer (containing dithiothreitol (DDT), Beyotime) to the same protein concentration to make a volumetric solution, and further reduce and denature at 100℃ for 10 minutes; 5) Separate the above sample (10-20 μg of protein) by SDS-PAGE and transfer it to a PVDF membrane (Biorad); 6) Cut out the bands according to the molecular weight of the target protein, block them with blocking solution (3% bovine serum albumin TBS-T solution, in which TBS-T solution is Tris-HCl buffer containing 0.2% Tween-20) for 1 hour, and further incubate them at 4℃ overnight with primary antibodies (anti-AR (#5153, CST), anti-PSA / KLK3 (#5365, CST) and anti-β-actin (#4970, CST), prepared by diluting the blocking solution at 1:1000, 1:1000 and 1:2000, respectively); 7) Finally, the membrane was incubated with HRP-conjugated secondary antibody (anti-rabbit IgG (#7074, CST), prepared by diluting 1:2000 in blocking solution) at room temperature for 1 hour, and then the bands on the membrane were detected with a chemiluminescent substrate (Clarity ECL, Biorad).

[0186] Test Results: The test results are shown in Figures 1 and 2. Conclusion: The compounds of the present invention show good decomposition activity against AR protein, and their decomposition ability shows good concentration dependency; the compounds of the present invention can significantly affect the corresponding downstream PSA effect changes, and the degree of their effect shows good concentration dependency.

[0187] Test Example 2: Evaluation of antiproliferative effects in human prostate cancer LNCaP cells Purpose of the Test: This experiment detects the inhibitory effect of test compounds on cell proliferation in human prostate cancer LNCaP cells. Test materials: 1. Cell lines and culture methods [Table 1]

[0188] 2. Media and Reagents [Table 2]

[0189] 3. Multiwell Plates Greiner CELLSTAR® 96-well plate, flat bottom black plate (with lid and clear bottom), #655090.

[0190] 4. Cellular activity experiment reagents and equipment (1) Promega CellTiter-Glo Luminescent Cell Activity Detection Kit (Promega-G7573). (2) 2104 EnVision® Plate Reader, PerkinElmer.

[0191] Experimental scheme 1. Cell Culturing Tumor cell lines were cultured according to the above culture conditions in a 5% CO2 incubator at 37°C. They were passaged periodically, and cells in the logarithmic growth phase were harvested for plating. 2. Cell Plating (1) Stain the cells with trypan blue and count the viable cells; (2) Adjust the cell concentration to an appropriate concentration; [Table 3] (3) Add cell suspension at 90 μL / well to culture plates as shown in the table above, and add cell-free medium to blank control wells; (4) The culture plate was incubated overnight in an incubator at 37°C, 5% CO2, and 100% relative humidity.

[0192] 3. Preparation of Compound Storage Plates Prepare a stock plate of 400x the starting concentration of compound: Compounds were diluted in DMSO from highest to lowest concentration gradient. Prepare each time for use. Preparation of 10x working solutions of compounds starting concentration and cell treatment with compounds: (1) 78 μL of cell culture medium was added to a V-bottom 96-well plate, and 2 μL of compound was pipetted from a mother liquor storage plate with a concentration 400 times higher than the starting concentration of the compound, and added to the cell culture medium in the 96-well plate. 2 μL of DMSO was added to the solvent control and blank control. After adding the compound or DMSO, the mixture was pipetted evenly with a pipette. (2) Administration: 10 μL of a working solution of 10 times the initial concentration of the compound was taken and added to the cell culture plate. 10 μL of DMSO-cell medium mixed solution was added to the solvent control and blank control. (3) The 96-well cell plate was returned to the incubator and cultured for 6 days.

[0193] 5. Detection of cell activity using CellTiter-Glo luminescence assay The following procedure was carried out according to the instructions for the Promega CellTiter-Glo Luminescent Cell Activity Detection Kit (Promega-G7573). (1) Dissolve CellTiter-Glo buffer and leave at room temperature; (2) Allow the CellTiter-Glo substrate to stand at room temperature; (3) Add 100 mL of CellTiter-Glo buffer to one bottle of CellTiter-Glo substrate to dissolve the substrate, preparing a CellTiter-Glo working solution; (4) Gently vortex to dissolve completely; (5) Take the cell culture plate and leave it at room temperature for 30 minutes to equilibrate; (6) Add 50 μL of CellTiter-Glo working solution to each well (equivalent to half the volume of cell culture medium in each well). Wrap the cell plate in aluminum foil to avoid light exposure; (7) Shake the culture plate on an orbital shaker for 2 minutes to induce cell lysis; (8) Leave the culture plate at room temperature for 10 minutes to stabilize the luminescence signal; (9) Luminescence signals were detected using a 2104 EnVision plate reader.

[0194] 6. Data Analysis The inhibition rate (IR) of the test compound was calculated by the following formula: IR (%) = (1-(RLU solvent control-RLU compound) / (RLU solvent control-RLU blank control) x 100%. The inhibition rates of different concentrations of the compounds were calculated using Excel, and the inhibition curves were plotted using GraphPad Prism software, and the minimum inhibition rate, maximum inhibition rate and IC 50 The relevant parameters were calculated, including:

[0195] Test Results: The experimental results are shown in Table 4. [Table 4] Conclusion: The compounds of the present invention show excellent cell proliferation inhibitory effects in human prostate cancer cells LNCaP.

[0196] Test Example 3: In vivo efficacy study of human prostate cancer LNCaP cell subcutaneous xenograft tumor CB-17 SCID model Cell culture Human prostate cancer LNcap cells (ECACC-89110211) were cultured in vitro in monolayer in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin in a 37°C, 5% CO2 incubator. The cells were subcultured twice a week after routine digestion using trypsin-EDTA. When the cell saturation was 80%-90% and the cell number reached the required level, the cells were collected, counted, and inoculated.

[0197] Experimental animals CB-17 SCID mice, 6–8 weeks old, male, weighing 18–22 g. Experimental scheme Each mouse was injected with 0.2 mL (1 × 10 7 LNcap cells (containing Matrigel, volume ratio 1:1) were inoculated subcutaneously, and the average tumor volume was 80 mm 3 Mice were surgically castrated when they reached a body mass of 166 mm. 3 When the animals reached this age, they were divided into groups and administration was started. The grouping of the experimental animals and the administration method are shown in Table 5. [Table 5] Note: 1.N: Number of mice in each group 2. Dosing volume: 10 μL / g based on mouse weight. If weight loss exceeds 15%, the dosing schedule should be adjusted accordingly. 3. The BID time interval is 8 hours. Tumor measurements and laboratory endpoints Tumor diameters were measured twice a week with a caliper. Tumor volume was calculated using the formula: V = 0.5a × b 2 where a and b represent the long and short diameters of the tumor, respectively. The antitumor effect of a compound is evaluated by TGI (%). TGI (%) reflects the tumor growth inhibition rate. TGI (%) = [(1-(mean tumor volume at the end of treatment for a particular treatment group-mean tumor volume at the start of treatment for that treatment group) / (mean tumor volume at the end of treatment for the vehicle control group-mean tumor volume at the start of treatment for the vehicle control group)] x 100%.

[0198] Experimental Results The experimental results are shown in Table 6. [Table 6] Conclusion: The compounds of the present invention show significant tumor-inhibitory effects in human prostate cancer LNCaP xenograft tumor model.

[0199] Test Example 4: In vitro study of the regulation of AR protein levels in human prostate cancer LNCaP cells Experimental Objective: To test the degrading effect of compounds on androgen receptor AR in LNCaP cells by ICW method.

[0200] Testing Method: Day 1 1. Pre-heat cell culture medium, 0.025% trypsin and phosphate buffer in a 37°C water bath. 2. Trypsin-digested cells were centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, and the cells were then resuspended in fresh medium. 3. Cells were seeded onto COL-Coated CellCarrier-384 plates at a density of 4k / 36 μL / well. 4. The inoculated 384 cell plate was placed on an ultra-clean workbench for 10 minutes. 5. The cell plate was cultured overnight in a CO2 cell incubator.

[0201] Day 2 Compounds at a concentration of 1.10 mM were diluted to 3 mM (3 μL + 7 μL dimethylsulfoxide) prior to serial dilution. 2. Compounds were serially diluted 3-fold (4 μL + 8 μL) in an Echo plate using the Bravo instrument. 3. ZPE and HPE control wells were set up, ZPE control wells were dimethylsulfoxide. 4. The Echo plate was centrifuged at 1000 rpm for 1 minute, then the diluted compounds were transferred from the Echo plate to the middle plate using the Echo at 200 nL / well. 5. Cell culture medium was added to the middle plate at 20 μL / well using the Multidrop combi. 6. The middle plate was placed on a horizontal shaker and shaken for 1 minute to thoroughly mix the compound and medium. 7. Compounds were transferred from the intermediate dilution plate to the cell plate using a Bravo at 4 μL / well. 8. The cell plate was placed on a horizontal shaker, shaken for 1 minute, and centrifuged at 800 rpm for 30 seconds. 9. The cell plate was returned to the CO2 incubator and culture was continued for 24 hours.

[0202] Day 3 Remove the 1.4% paraformaldehyde from the refrigerator and allow it to come to room temperature. 2. The cell plate was removed from the incubator. 3. 4% paraformaldehyde was added directly to the cell plates at 40 μL / well. 4. Incubated at room temperature for 20 minutes. 5. The medium on the cell plate was manually shaken off, and the plate was inverted in a centrifuge and centrifuged at 800 rpm for 7 seconds to completely remove residual medium. 6. 4% paraformaldehyde was added to the cell plates at 25 μL / well. 7. Incubate at room temperature for 30 minutes. 8. The paraformaldehyde solution was manually shaken off from the cell plate, and the plate was then inverted in a centrifuge and centrifuged at 800 rpm for 7 seconds. 9. 0.1% Trition was added at 25 μL / well. 10. Incubate at room temperature for 10 minutes. 11. The 0.1% Trition solution was manually shaken off from the cell plate, and the plate was then inverted in a centrifuge and centrifuged at 800 rpm for 7 seconds. 12. Intercept® (PBS) Blocking Buffer was added at 25 μL / well. 13. Incubated at room temperature for 1 hour. 14. Manually shake off the Intercept® (PBS) Blocking Buffer solution from the cell plate, invert it in a centrifuge, and centrifuge at 800 rpm for 7 seconds. 15. Primary antibody solution was added at 20 μL / well. The cell plate was placed in the centrifuge and centrifuged at 800 rpm for 7 seconds. 16. The cell plates were sealed and then incubated overnight at 4°C.

[0203] Day 4 1. Manually shake off the primary antibody solution from the cell plate, invert it in a centrifuge, and centrifuge at 800 rpm for 7 seconds. 2. Wash three times with 110 μL of PBS. 3. The cell plate was inverted in a centrifuge and spun at 800 rpm for 7 seconds. 4. Secondary antibody and DAPI solution were added at 20 μL / well. The cell plate was placed in a centrifuge and centrifuged at 800 rpm for 7 seconds. 5. Incubated at room temperature for 1 hour. 6. Manually shake off the secondary antibody and DAPI solution from the cell plate, then place in a centrifuge and centrifuge at 800 rpm for 7 seconds. 7.1 Wash three times with 10 μL of PBS, leaving 30 μL of PBS on the cell plate. 8. The cell plate was placed in the centrifuge and centrifuged at 800 rpm for 7 seconds. 9. The cell plates were scanned with the Operetta instrument.

[0204] Experimental Results The experimental results are shown in Table 4. [Table 7] Conclusion: The compounds of the present invention show good decomposition activity against AR.

[0205] Test Example 5: In cell western analysis of AR protein expression levels in 293T AR F876L cells Experimental Objective: This experiment is to detect the effect of compounds WX015, WX016 and WX017 on the expression level of AR protein of point mutation in cell line 293T AR F876L by In Cell Western experiment, and evaluate the decomposition effect of compounds on AR F876L point mutation protein.

[0206] Test materials: 1. Cell lines and culture methods [Table 8] 2. Media and Reagents [Table 9]

[0207] 3.Equipment [Table 10]

[0208] 4. Antibodies [Table 11]

[0209] Testing Method: 1. Cell Culture: The cell lines were cultured in an incubator at 37°C with 5% CO2. They were passaged periodically, and cells in the logarithmic growth phase were harvested for plating.

[0210] 2. Cell plating: 1) Cells were stained with trypan blue and viable cells were counted. 2) The cell concentration was adjusted to an appropriate concentration, with a density of 20,000 / well. 3) The cell suspension was added to a 96-well culture plate at 90 μL / well, and cell-free medium was added to blank control wells. 4) The culture plate was incubated overnight in an incubator at 37°C, 5% CO2, and 100% relative humidity.

[0211] 3. Preparation of Compound Storage Plates and In Cell Western Detection: 1) Preparation of 400-fold compound stock plate: Compounds were gradient diluted in DMSO from highest to lowest concentration. 2) Preparation of 10x compound working solution: 78μL of cell culture medium was added to a V-bottom 96-well plate, and 2μL of compound from the 400X compound stock plate was pipetted and added to the cell culture medium in the 96-well plate. 2μL of DMSO was added to the solvent control and blank control. After compound or DMSO was added, the mixture was pipetted evenly. 3) Dosing: 10 μL of 10x compound working solution was taken and added to the cell culture plate. 10 μL of DMSO-cell medium mixed solution was added to the solvent control and blank control. The final concentration of DMSO was 0.25%. 4) The 96-well cell plate was returned to the incubator and cultured for 48 hours. 5) The medium was removed and the cells were washed once with PBS. 6) 8% formalin solution (diluted with PBS) was added and the cells were cultured overnight at 4°C. 7) The 8% formalin solution was removed, and 150 μL of Licor Blocking buffer was added to each well. The wells were then placed on a shaker at room temperature for 1.5 hours for blocking. 8) Discard the blocking solution and add 50 μL of primary antibody diluted with Licor Blocking buffer to each well (no primary antibody was added to DMSO wells). Incubate overnight at 4°C and then wash five times with PBST (containing 0.1% Triton-X) for 5 min each time. 9) Secondary antibody diluted with 50 μL of Licor Blocking buffer was added to each well, and the wells were incubated at room temperature for 1 hour. After that, the wells were washed three times with PBST (containing 0.1% Triton-X) and twice with ddH2O. An additional 100 μL of PBS was added to each well to prepare for detection. 10) Detection: The PBS in the well plate was discarded, and the fluorescent signal was detected at 700 nm / well using a Li-COR odyssey two-color near-infrared imager.

[0212] 4. Data Analysis Relative quantification of the density intensity of Western blotting immunochemiluminescent bands was performed using Image Studio Ver 5.2 software.

[0213] Experimental Results The experimental results are shown in Table 12. [Table 12] Conclusion: The compounds of the present invention have strong ability to degrade F876L point mutant AR protein.

[0214] Test Example 6: Pharmacokinetic evaluation of compounds in mice Purpose of the test: The test compounds in this study were selected as CB-17 SCID male mice, and the LCMS / MS method was used to quantitatively measure the plasma drug concentrations of the test compounds and reference compounds at different times after intravenous injection or oral administration to the mice, and to evaluate the pharmacokinetic properties of the test compounds in mice.

[0215] Test materials: CB-17 SCID mice (male, 20-30 g, 7-10 weeks old, Beijing Vital River or Shanghai SLAC). Experimental Procedure: Clear solutions or suspensions of test compounds were injected into mice via the tail vein (unfasted) or administered intragastrically (unfasted). For intravenous injection, blood was collected by jugular vein puncture at 0 h (before dosing) and 0.083, 0.25, 0.5, 1, 2, 4, 8, 24 h after dosing, placed in anticoagulant tubes with EDTA-K2, mixed thoroughly by vortexing, and centrifuged at 13000 rpm for 10 min at 4°C; for intragastric administration, blood was collected by jugular vein puncture at 0 h (before dosing) and 0.5, 1, 2, 4, 6, 8, 24 h after dosing, placed in anticoagulant tubes with EDTA-K2, mixed thoroughly by vortexing, and centrifuged at 13000 rpm for 10 min. Plasma concentrations were measured using LC-MS / MS method and analyzed by WinNonlin TM Pharmacokinetic parameters were calculated using the noncompartmental model linear-log ladder method using Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software.

[0216] Experimental Results: The test results are shown in Table 13. [Table 13] Conclusion: The compounds of the present invention show good druggability in mice.

[0217] Test Example 7: Pharmacokinetic evaluation of compounds in rats Purpose of the test: The test compounds in this study were selected as SD male rats, and the LCMS / MS method was used to quantitatively measure the plasma drug concentrations of the test compounds and reference compounds at different times after intravenous injection or oral administration to the rats, and to evaluate the pharmacokinetic properties of the test compounds in rats. Test materials: SD rat (male, Beijing Vital River).

[0218] Experimental Procedure: Rats were injected with clear solutions or suspensions of test compounds via the tail vein (not fasted) or administered intragastrically (not fasted). For intravenous injection, blood was collected by jugular vein puncture at 0 h (before administration) and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 48 h after administration, and placed in anticoagulant tubes with added sodium heparin, blood samples were collected and placed on ice, and plasma was centrifuged within 1 h (centrifugation conditions: 6000 g, 3 min, 2-8 ° C); for intragastric administration, blood was collected by jugular vein puncture at 0 h (before administration) and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 48 h after administration, and placed in anticoagulant tubes with added sodium heparin, blood samples were collected and placed on ice, and plasma was centrifuged within 1 h (centrifugation conditions: 6000 g, 3 min, 2-8 ° C). Plasma concentrations were measured using an LC-MS / MS method, and pharmacokinetic parameters were calculated using the non-compartmental model linear log-ladder method with WinNonlin™ Version 8.2.0 (Pharsight, Mountain View, Calif.) pharmacokinetic software. Experimental Results: The test results are shown in Table 14. [Table 14] Conclusion: The compounds of the present invention show good druggability in rats.

[0219] Test Example 8: Pharmacokinetic evaluation of compounds in beagles Purpose of the test: The test compound in this study was selected as beagles, and the LCMS / MS method was used to quantitatively measure the plasma drug concentrations of the test compounds and reference compounds at different times after intravenous injection or oral administration to beagles, and to evaluate the pharmacokinetic properties of the test compounds in beagles. Test materials: Beagle (male, Jiangsu Yadong Institute of Experimental Animals Co., Ltd.).

[0220] Experimental Procedure: Clear solutions or suspensions of the test compounds were either injected via the tail vein into beagles (normally fed) or administered intragastrically to beagles (normally fed). For intravenous injection, blood was collected by puncturing the forelimb vein at 0 h (before administration) and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 48 h after administration, and placed in an anticoagulant tube with added EDTA-2K. Blood samples were collected and placed on ice, and the plasma was centrifuged within 1 hour (centrifugation conditions: 6000 g, 3 min, 2-8 ° C); for intragastric administration, blood was collected by puncturing the forelimb vein at 0 h (before administration) and 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 48 h after administration, and placed in an anticoagulant tube with added EDTA-2K. Blood samples were collected and placed on ice, and the plasma was centrifuged within 1 hour (centrifugation conditions: 6000 g, 3 min, 2-8 ° C). Plasma concentrations were measured using an LC-MS / MS method, and pharmacokinetic parameters were calculated using the noncompartmental model linear log ladder method with WinNonlin™ Version 8.2.0 (Pharsight, Mountain View, Calif.) pharmacokinetic software.

[0221] Experimental Results: The test results are shown in Table 15. [Table 15] Conclusion: The compounds of the present invention show good druggability in beagles.

Claims

1. A compound represented by formula (II) or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (however, PTM is 【Chemistry 2】 is selected from L １ teeth, 【Chemistry 3】 is selected from E １ is selected from a single bond and O; Ring A is absent, Or ring A is phenyl.

2. Structural unit-E １ -L １ -teeth, 【Chemistry 4】 2. The compound of claim 1, selected from:

3. Structural Units 【Chemistry 5】 2. The compound of claim 1, selected from:

4. The compound according to any one of claims 1 to 3, wherein the compound is selected from the structures represented by formulas (I-1), (I-2), (II-1), (II-2), (III-1) and (IV-1), or a pharma- ceutically acceptable salt thereof. 【Chemistry 6】 (However, L １ is as defined in claim 1 or claim 2.

5. A compound represented by the following formula or a pharma- ceutically acceptable salt thereof: 【Chemistry 7】 【Chemistry 8】

6. A compound selected from the formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】

7. 13. Use of a compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating prostate cancer.

Images